Month: October 2026

TORONTO, Oct. 28, 2026 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to report results from the final 89 drill holes of its completed Phase 2 drill program at the 100%-owned Pardo “River of Gold” Project, located 65 km northeast of Sudbury, Ontario. The latest results include 4.47 g/t gold over 2.19 m and 3.39 g/t gold over 2.19 m in the shallow Main Layer (“MiBC”).

These final Phase 2 results will be incorporated into the Company’s upcoming maiden mineral resource estimate, targeted for mid-November 2026. With Phase 3 drilling already underway, Inventus is advancing its initial resource estimate while testing the potential to expand the Pardo gold system into a substantially larger area.

HIGHLIGHTS

• Final Phase 2 assays complete the results from the 89 holes that remained pending in September. These results add to the drill data supporting the upcoming maiden mineral resource estimate.
• Shallow Main Layer results include:
  • 4.47 g/t gold over 2.19 m, including 12.41 g/t gold over 0.50 m, beginning 10.81 m below surface in PD-26-404.
  • 3.39 g/t gold over 2.19 m, including 16.01 g/t gold over 0.30 m, beginning 14.98 m below surface in PD-26-406.
  • 3.31 g/t gold over 1.66 m, including 7.25 g/t gold over 0.62 m, beginning 9.41 m below surface in PD-26-422.
  • 2.37 g/t gold over 2.33 m, including 8.63 g/t gold over 0.40 m, beginning 12.98 m below surface in PD-26-424.
  • 1.79 g/t gold over 4.10 m, including 4.84 g/t gold over 1.42 m, beginning 8.86 m below surface in PD-26-463.
  • 1.65 g/t gold over 2.39 m, including 3.71 g/t gold over 0.93 m, beginning 9.50 m below surface in PD-26-480.
• Broader gold-bearing intervals span the Main Layer and Matinenda Conglomerate (“MaC”), including 0.97 g/t gold over 5.15 m in PD-26-486 and 0.51 g/t gold over 10.26 m in PD-26-487.
• Phase 3 drilling is underway, with approximately 6,000 metres in 155 holes planned to expand the area tested by drilling from 1.2 km² to 3.55 km².

Wesley Whymark, CEO & Director, comments: “These results give us a strong finish to the Phase 2 drill program. We continue to see high-grade gold in the Main Layer close to surface, together with broader gold-bearing intervals across the stacked layers. Hole PD-26-404 is a great example, returning 4.47 g/t gold over 2.19 metres starting less than 11 metres below surface.”

“With the Phase 2 drilling now complete, we can bring the full set of results into our maiden resource estimate. That is an important milestone for Pardo. At the same time, Phase 3 is designed to expand the area tested by drilling to almost three times its current size. We have a lot to look forward to as we advance the shallow Main Layer DSO opportunity and test the different gold-bearing layers to see how large this gold system could become.”

FINAL PHASE 2 DRILLING RESULTS

The final 89 holes follow the results from 100 holes reported on September 23, 2026. Selected assay intervals are presented in Table 1, with collar details in Table 2. The locations of the holes reported in this release are shown in Figure 1.

The Main Layer continues to return higher-grade gold close to surface. These results support the Company’s focus on the shallow part of the Main Layer for its direct ship ore (“DSO”) strategy, which aims to deliver material to an existing processing facility. Higher-grade intervals occur within the Main Layer that also contains wider intervals of lower-grade gold mineralization.

Additional Main Layer results include 2.56 g/t gold over 1.06 m in PD-26-418, 1.54 g/t gold over 2.45 m in PD-26-419 and 1.33 g/t gold over 2.78 m in PD-26-459. The final drilling, together with the Company’s bulk sampling data, will provide important information on how gold grades vary within the Main Layer and help define the geological model and geostatistical analysis for the maiden mineral resource estimate.

Pardo’s gold occurs in several nearly horizontal rock layers, including conglomerate, a rock made up of rounded pebbles held together by finer material. Because the holes were drilled vertically through these layers, the reported intervals approximate the true thickness of the mineralized rock. The simplified section in Figure 2 shows how the gold-bearing layers are stacked above and below the Main Layer.

Phase 3 will test these layers for additional areas of high-grade gold. Phase 2 drilling has demonstrated this potential in the Matinenda Layer, where PD-26-297 returned 2.82 g/t gold over 2.43 m, including 10.51 g/t gold over 0.50 m (see news release July 6, 2026).

BROADER GOLD MINERALIZATION ACROSS STACKED LAYERS

The results also add to the broader lower-grade gold opportunity described in the September 23, 2026 news release. In the western part of the drilled area, PD-26-485 returned 0.45 g/t gold over 9.77 m, PD-26-486 returned 0.97 g/t gold over 5.15 m and PD-26-487 returned 0.51 g/t gold over 10.26 m. These intervals span both the Main Layer and the underlying Matinenda Conglomerate Layer, with higher-grade sections within the broader mineralized intervals.

Gold was also returned from layers above the Main Layer, including 0.24 g/t gold over 3.93 m in the Upper Conglomerate (“MiPC”) in PD-26-482 and 0.34 g/t gold over 3.66 m in the Lower Sandstone (“MiBS”) in PD-26-487. Together, the results add further evidence of gold mineralization across multiple layers at Pardo (Figure 2).

Some of these lower-grade intervals may not be economic on their own but could still have value where they must be removed to access the Main and Matinenda layers. If this material can be processed, which may include heap leaching, gold recovered from these layers could help offset part of the cost of removing rock that would otherwise be treated as waste. The lower-grade material will be further tested, and any potential cost benefit remains subject to metallurgical testing and economic evaluation.

The shallow, higher-grade Main Layer remains the focus of the DSO strategy, while the wider intervals across several layers provide a broader bulk-tonnage opportunity for evaluation. Additional exploration could also identify higher-grade areas within the Matinenda, Upper Conglomerate and Lower Sandstone layers, potentially adding to Pardo’s overall scale and development options. Further resource estimation, metallurgical testwork and economic studies will be needed to determine what material could be developed economically.

MAIDEN RESOURCE ESTIMATE AND PHASE 3 DRILLING

All Phase 2 drilling results, including the final assays reported today, will be incorporated into the upcoming maiden mineral resource estimate, targeted for mid-November 2026. The initial estimate will cover the previously drilled area and is intended to provide a resource foundation for advancing the Company’s DSO plan.

As announced on October 20, 2026, Phase 3 drilling commenced on October 14. The approximately 6,000-metre, 155-hole program is designed to test an additional 2.35 km² of favourable geology, expanding the area tested by drilling from 1.2 km² to 3.55 km². The program will test extensions of the Main Layer and other gold-bearing layers, with the goal of supporting a potentially larger mineral resource estimate in the future.

Phase 3 will also test the shallow, sulphide-rich Matinenda Layer in the western part of the project. Inventus is evaluating whether this material can be upgraded through ore sorting to produce a second potential DSO product. Further metallurgical testing and commercial evaluation are required.

NEXT STEPS

• Complete the maiden mineral resource estimate, targeted for mid-November 2026, incorporating the full Phase 2 drill results.
• Advance Phase 3 drilling and report results as available.
• Continue advancing the Main Layer DSO strategy and metallurgical and ore-sorting testwork on the Matinenda Conglomerate.
• Advance plans to resume bulk sampling, with approximately 10,000 tonnes stockpiled and a further 20,000 tonnes permitted for extraction.

For further information visit www.inventusmining.com, or contact:

Wesley Whymark
CEO & Director
Inventus Mining Corp.
E-mail: wesley@inventusmining.com
Phone: 705-822-3005

Social Media Accounts

https://x.com/InventusMining
http://ca.linkedin.com/company/inventus-mining
https://www.youtube.com/@inventusmining
https://www.facebook.com/people/Inventus-Mining/61587627317147/ 

Figure 1. Plan map showing the locations of the final 89 Phase 2 drill holes reported in this release and previously reported Phase 2 drilling.

Figure 2. Simplified geological section illustrating the shallow, stacked gold-bearing layers at the Pardo “River of Gold” Project, including the MiPC, MiBS, Main Layer (MiBC) and Matinenda Layer (MaC).

Table 1. Final Phase 2 drilling assay highlights.

Drill Hole	From (Metres)	To (Metres)	Zone1	Interval2 (Metres)	Gold Grade (g/t)
PD-26-388	15.00	16.54	MiBC	1.54	0.37
PD-26-389	8.25	12.00	MiBC	3.75	0.49
Including	9.69	10.08	MiBC	0.39	1.19
PD-26-390	7.56	12.92	MiBC	5.36	0.47
Including	11.50	12.91	MiBC	1.41	1.37
Including	12.41	12.91	MiBC	0.50	2.37
PD-26-402	9.67	12.58	MiBC	2.91	0.60
Including	11.11	12.58	MiBC	1.47	1.03
Including	12.11	12.58	MiBC	0.47	2.53
PD-26-403	9.36	10.29	MiBC	0.93	0.72
PD-26-404	10.81	13.00	MiBC	2.19	4.47
Including	11.23	12.50	MiBC	1.27	7.26
Including	11.23	11.73	MiBC	0.50	12.41
PD-26-405	13.05	14.60	MiBC	1.55	1.04
Including	13.55	14.22	MiBC	0.67	1.92
PD-26-406	14.98	17.17	MiBC	2.19	3.39
Including	15.34	15.95	MiBC	0.61	9.40
Including	15.65	15.95	MiBC	0.30	16.01
PD-26-407	3.50	7.00	MiPC	3.50	0.25
And	14.50	18.02	MiBC	3.52	0.37
Including	16.26	18.02	MiBC	1.76	0.61
Including	16.26	16.76	MiBC	0.50	1.26
PD-26-408	6.27	12.38	MiBC	6.11	0.49
Including	11.00	12.38	MiBC	1.38	1.73
Including	11.37	11.67	MiBC	0.30	5.23
PD-26-409	7.83	10.83	MiBC	3.00	0.32
Including	10.13	10.83	MiBC	0.70	0.73
PD-26-410	8.51	11.71	MiBC	3.20	0.95
Including	10.42	11.71	MiBC	1.29	2.16
Including	10.82	11.23	MiBC	0.41	5.73
PD-26-411	10.29	12.31	MiBC	2.02	0.39
Including	11.00	12.31	MiBC	1.31	0.50
PD-26-412	13.06	16.00	MiBC	2.94	0.99
Including	15.04	16.00	MiBC	0.96	2.41
PD-26-413	1.50	2.95	MiPC	1.45	0.26
And	13.63	14.66	MiBC	1.03	1.51
Including	14.23	14.66	MiBC	0.43	3.02
PD-26-414	0.62	2.87	MiPC	2.25	0.34
And	11.66	14.85	MiBC	3.19	1.25
Including	12.16	12.85	MiBC	0.69	3.73
PD-26-416	14.35	17.80	MiBC	3.45	0.82
Including	16.65	17.42	MiBC	0.77	1.68
PD-26-418	11.62	12.68	MiBC	1.06	2.56
Including	12.00	12.34	MiBC	0.34	4.77
PD-26-419	9.47	11.92	MiBC	2.45	1.54
Including	10.19	11.10	MiBC	0.91	3.70
PD-26-420	9.60	10.73	MiBC	1.13	1.19
Including	10.22	10.47	MiBC	0.25	3.43
PD-26-421	9.00	11.05	MiBC	2.05	0.81
Including	10.67	11.05	MiBC	0.38	2.89
PD-26-422	9.41	11.07	MiBC	1.66	3.31
Including	10.15	10.77	MiBC	0.62	7.25
PD-26-423	10.13	11.48	MiBC	1.35	0.35
PD-26-424	12.98	15.31	MiBC	2.33	2.37
Including	12.98	14.38	MiBC	1.40	3.58
Including	13.48	13.88	MiBC	0.40	8.63
PD-26-430	14.00	15.50	MiPC	1.50	0.32
and	29.20	31.58	MiBS	2.38	0.45
Including	31.22	31.58	MiBS	0.36	1.49
and	36.10	37.50	MaC	1.40	0.30
PD-26-432	29.01	29.45	MaC	0.44	1.48
PD-26-433	23.36	27.21	MiBC	3.85	0.31
PD-26-435	13.55	15.33	MiBC	1.78	0.41
PD-26-438	0.43	3.63	MiBC	3.20	0.44
Including	0.43	0.86	MiBC	0.43	1.46
PD-26-441	4.83	6.13	MiBC	1.30	0.51
Including	4.83	5.15	MiBC	0.32	1.35
PD-26-443	13.48	13.84	MaC	0.36	1.19
PD-26-444	7.54	10.34	MiBC	2.80	0.35
Including	9.94	10.34	MiBC	0.40	1.31
PD-26-445	4.00	4.96	MiBC	0.96	1.65
PD-26-447	2.90	5.19	MiBC	2.29	0.61
Including	3.39	3.86	MiBC	0.47	2.22
PD-26-448	0.58	4.50	MiBC	3.92	0.53
Including	0.96	1.47	MiBC	0.51	2.03
And	8.19	10.26	MaC	2.07	0.44
Including	9.96	10.26	MaC	0.30	1.38
PD-26-450	4.00	5.45	MiBC	1.45	0.41
PD-26-452	0.18	0.48	MiBC	0.30	4.05
And	5.55	7.54	MaC	1.99	0.25
PD-26-455	10.67	11.79	MiBC	1.12	2.44
Including	10.67	11.00	MiBC	0.33	4.12
PD-26-456	10.18	11.37	MiBC	1.19	2.10
Including	10.58	10.99	MiBC	0.41	4.65
PD-26-458	1.54	5.72	MiBC	4.18	0.21
And	12.30	13.84	MiBC	1.54	0.71
PD-26-459	1.90	3.78	MiPC	1.88	0.31
And	10.91	13.69	MiBC	2.78	1.33
Including	11.84	13.69	MiBC	1.85	1.87
Including	13.28	13.69	MiBC	0.41	5.87
PD-26-460	2.88	5.54	MiPC	2.66	0.26
And	9.07	10.35	MiBC	1.28	1.10
Including	9.90	10.35	MiBC	0.45	2.71
PD-26-462	4.24	11.36	MiBC	7.12	0.28
PD-26-463	0.98	3.00	MiBC	2.02	0.24
And	8.86	12.96	MiBC	4.10	1.79
Including	10.53	12.96	MiBC	2.43	2.92
Including	11.04	12.46	MiBC	1.42	4.84
Including	12.00	12.46	MiBC	0.46	6.97
PD-26-464	9.53	11.25	MiBC	1.72	0.78
Including	10.40	11.25	MiBC	0.85	1.46
Including	10.84	11.25	MiBC	0.41	2.19
PD-26-465	9.50	11.40	MiBC	1.90	1.81
Including	10.46	11.40	MiBC	0.94	3.42
PD-26-466	0.51	1.97	MiBC	1.46	0.26
And	9.53	12.00	MiBC	2.47	0.30
PD-26-467	13.08	15.45	MiBC	2.37	0.32
PD-26-468	0.40	1.88	MiBC	1.48	0.24
And	10.31	11.67	MiBC	1.36	2.36
Including	11.21	11.67	MiBC	0.46	6.33
PD-26-469	10.89	12.51	MiBC	1.62	0.84
Including	12.04	12.51	MiBC	0.47	1.28
PD-26-470	0.47	2.26	MiBC	1.79	0.32
And	10.51	12.65	MiBC	2.14	0.38
PD-26-471	1.39	3.52	MiBC	2.13	0.26
And	10.50	13.69	MiBC	3.19	0.87
Including	12.78	13.69	MiBC	0.91	2.68
Including	12.78	13.20	MiBC	0.42	5.24
PD-26-472	0.70	1.62	MiBC	0.92	0.29
And	9.60	11.04	MiBC	1.44	0.58
Including	10.05	10.54	MiBC	0.49	1.14
PD-26-473	0.03	1.21	MiBC	1.18	0.18
And	8.91	10.61	MiBC	1.70	1.33
Including	9.48	9.88	MiBC	0.40	3.63
PD-26-474	5.69	6.65	MiBC	0.96	0.32
PD-26-476	12.10	13.55	MiBC	1.45	1.59
Including	13.09	13.55	MiBC	0.46	4.30
PD-26-477	15.62	16.29	MiBC	0.67	0.90
PD-26-478	8.00	12.98	MiBC	4.98	0.52
Including	12.64	12.98	MiBC	0.34	1.67
PD-26-479	9.23	13.64	MiBC/MaC	4.41	0.87
Including	11.19	11.67	MiBC	0.48	5.59
Including	12.14	13.64	MaC	1.50	0.30
PD-26-480	9.50	11.89	MiBC	2.39	1.65
Including	10.50	11.43	MiBC	0.93	3.71
And	12.73	14.38	MaC	1.65	0.30
PD-26-481	39.77	42.74	MaC	2.97	0.31
PD-26-482	6.23	10.16	MiPC	3.93	0.24
And	35.30	40.70	MaC	5.40	0.33
PD-26-483	32.70	36.54	MaC	3.84	0.32
And	38.54	42.00	MaC	3.46	0.28
PD-26-484	7.17	9.11	MiPC	1.94	0.29
And	23.17	26.17	MiBC	3.00	0.44
Including	25.87	26.17	MiBC	0.30	1.71
And	30.58	34.09	MaC	3.51	0.31
PD-26-485	28.84	38.61	MiBC/MaC	9.77	0.45
Including	29.19	29.55	MiBC	0.36	3.63
Including	37.20	38.61	MaC	1.41	1.17
PD-26-486	25.47	27.33	MiBS	1.86	0.26
And	30.20	35.35	MiBC/MaC	5.15	0.97
Including	30.70	32.00	MiBC	1.30	2.83
Including	31.64	32.00	MiBC	0.36	8.54
Including	33.87	35.35	MaC	1.48	0.68
PD-26-487	15.29	18.95	MiBS	3.66	0.34
And	26.90	37.16	MiBC/MaC	10.26	0.51
Including	29.60	31.32	MiBC	1.72	1.36
Including	30.52	30.94	MiBC	0.42	4.73
Including	34.74	35.24	MaC	0.50	1.56
PD-26-488	22.86	25.66	MiBS	2.80	0.21
And	27.46	30.04	MiBC	2.58	0.23
And	32.07	33.45	MiBC	1.38	0.32
And	37.25	38.83	MiBC	1.58	0.37
PD-26-489	24.60	26.30	MiBC	1.70	0.36
And	28.65	32.50	MiBC/MaC	3.85	0.28
1MiBC – Main Layer; MaC – Matinenda Layer; MiPC – Upper Conglomerate Layer; MiBS – Lower Sandstone.
2Interval width is approximate true thickness. Mineralization has a flat to 5-degree dip, and all holes were drilled vertically with an inclination of -90 degrees.

Table 2. Collar details for the final 89 Phase 2 drill holes. UTM coordinates are NAD 83 Zone 17.

Drill Hole	Inclination (Degrees)	Length (Metres)	Northing (UTM)	Easting (UTM)
PD-26-388	-90	19.5	5183432	556234
PD-26-389	-90	18	5183431	556267
PD-26-390	-90	17.3	5183432	556292
PD-26-400	-90	15.15	5183417	556311
PD-26-401	-90	15	5183416	556295
PD-26-402	-90	16.61	5183416	556267
PD-26-403	-90	19.5	5183417	556228
PD-26-404	-90	17.54	5183410	556201
PD-26-405	-90	18.9	5183395	556214
PD-26-406	-90	19	5183388	556240
PD-26-407	-90	20.5	5183401	556249
PD-26-408	-90	17.54	5183400	556267
PD-26-409	-90	14.57	5183401	556297
PD-26-410	-90	14.5	5183387	556301
PD-26-411	-90	16	5183384	556272
PD-26-412	-90	19	5183370	556261
PD-26-413	-90	17.5	5183347	556206
PD-26-414	-90	17.5	5183330	556218
PD-26-415	-90	16	5183308	556211
PD-26-416	-90	19	5183293	556190
PD-26-417	-90	17.5	5183302	556169
PD-26-418	-90	16	5183307	556153
PD-26-419	-90	14.5	5183308	556136
PD-26-420	-90	14.5	5183310	556121
PD-26-421	-90	14.5	5183295	556107
PD-26-422	-90	14.5	5183292	556131
PD-26-423	-90	16	5183276	556151
PD-26-424	-90	17.5	5183278	556203
PD-26-425	-90	13	5183280	556215
PD-26-430	-90	43	5183017	556777
PD-26-431	-90	38.5	5183131	556940
PD-26-432	-90	35.78	5183183	556910
PD-26-433	-90	38.5	5183202	556939
PD-26-434	-90	31	5183242	556945
PD-26-435	-90	26.5	5183308	556939
PD-26-436	-90	17.63	5183373	556944
PD-26-437	-90	29.5	5183442	556873
PD-26-438	-90	11.5	5183395	556608
PD-26-439	-90	11.54	5183412	556606
PD-26-440	-90	16	5183431	556618
PD-26-441	-90	16.01	5183451	556619
PD-26-442	-90	16	5183479	556619
PD-26-443	-90	17.63	5183503	556626
PD-26-444	-90	14.58	5183492	556611
PD-26-445	-90	16	5183465	556603
PD-26-446	-90	16	5183453	556600
PD-26-447	-90	13.12	5183425	556598
PD-26-448	-90	13	5183460	556581
PD-26-449	-90	14.23	5183479	556589
PD-26-450	-90	14.5	5183505	556617
PD-26-451	-90	10	5183496	556500
PD-26-452	-90	10	5183523	556501
PD-26-453	-90	8.5	5183499	556530
PD-26-454	-90	10	5183527	556525
PD-26-455	-90	13	5183259	556214
PD-26-456	-90	14.5	5183250	556200
PD-26-457	-90	17.5	5183264	556189
PD-26-458	-90	17.5	5183262	556164
PD-26-459	-90	16	5183269	556137
PD-26-460	-90	14.5	5183278	556121
PD-26-461	-90	11.5	5183278	556104
PD-26-462	-90	16	5183282	556085
PD-26-463	-90	17.5	5183237	556132
PD-26-464	-90	13	5183221	556128
PD-26-465	-90	13	5183205	556128
PD-26-466	-90	14.5	5183159	556133
PD-26-467	-90	19	5183227	556161
PD-26-468	-90	17.5	5183240	556193
PD-26-469	-90	16	5183225	556196
PD-26-470	-90	16	5183203	556187
PD-26-471	-90	16	5183176	556184
PD-26-472	-90	13	5183177	556203
PD-26-473	-90	13	5183195	556204
PD-26-474	-90	10	5183222	556217
PD-26-475	-90	8.5	5183239	556221
PD-26-476	-90	19	5183267	556334
PD-26-477	-90	20.5	5183268	556314
PD-26-478	-90	17.5	5183285	556311
PD-26-479	-90	16	5183318	556279
PD-26-480	-90	17.5	5183329	556306
PD-26-481	-90	44.5	5183263	555615
PD-26-482	-90	43	5183235	555640
PD-26-483	-90	44.5	5183284	555642
PD-26-484	-90	38.5	5183226	555687
PD-26-485	-90	40	5183267	555684
PD-26-486	-90	38.5	5183267	555757
PD-26-487	-90	38.5	5183232	555787
PD-26-488	-90	41.5	5183300	555798
PD-26-489	-90	35.5	5183262	555810

About Inventus Mining Corp.

Inventus is a mineral exploration and development company focused on the world-class mining district of Sudbury, Ontario. We have a 100% interest in our principal assets, the Pardo Paleoplacer Gold Project and the Sudbury 2.0 Critical Mineral Project, located northeast of Sudbury. The Pardo Gold Project is the first important paleoplacer gold discovery in North America. Inventus has approximately 221 million common shares outstanding.

Qualified Person

The Qualified Person responsible for the technical content of this news release is Wesley Whymark, P.Geo., who has reviewed and approved the technical disclosure in this news release on behalf of the Company.

Technical Information

Drill core samples collected by Inventus and described in this news release were subject to robust QA/QC protocols. PQ-size drill core was placed in core boxes by the contracted drill crew and then transported by Inventus personnel to a secure processing facility in Sudbury, Ontario. The core was reviewed, with core metreage blocks checked to verify core integrity and recovery, geologically logged, and sample intervals marked. Whole-core samples were then photographed and inserted into clean plastic bags with sample tags. Certified reference materials were inserted into the sample stream at a rate of no less than 10%.

Samples were then transported in secure sealed bags with security tags for preparation and assay by MSA Labs or Paragon Geochemical in Timmins, Ontario. Samples were processed, whereby the entire sample was crushed to 80% passing 2 mm and then riffle split into two (2) or three (3) 500-gram jars for gold analysis by PhotonAssay. When duplicate or triplicate samples were analyzed, the results were averaged. MSA Labs and Paragon Geochemical are both ISO 17025:2017 accredited geochemical testing laboratories.

Forward-Looking Statements

This News Release includes certain “forward-looking statements” which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “if”, “yet”, “potential”, “undetermined”, “objective”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to the failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Infographics accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/bd5e9027-f149-4ecd-bb1c-68c8009f7fc9

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e0e465a-63c1-4bcf-a1e3-d1c5efc59796

RALEIGH, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced it will release its third quarter 2026 financial and operational results after market close on Tuesday, November 10, 2026. The Company will host a conference call and live webcast to discuss the results at 5:00 p.m. ET.

The live audio webcast will be available in the Investor Relations section of the Company’s website at ir.lumexaimaging.com. A replay of the webcast will be available for approximately one year.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and approximately 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform. 

Media Contact
Melissa Weston
Melissa.Weston@LumexaImaging.com

IR Contact
Sue Dooley
Sue.Dooley@LumexaImaging.com

        

Third Quarter 2026 Financial Results to be Released After Market Close Monday, November 9, 2026

Management to Participate in Stephens’ Annual Investment Conference in Boston on November 17-19, 2026

WASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) — Public Policy Holding Company, Inc., (“PPHC” or “the Company”) (Nasdaq: PPHC) (AIM: PPHC.L), a leading global strategic communications provider offering a comprehensive range of advisory services in the areas of Government Relations, Public Affairs and Corporate Communications, today announced that it will release its financial results for the three and nine months ended September 30, 2026 (“Q3 2026 Results”) on Monday, November 9, 2026, after market close.

PPHC management will host a conference call to discuss the Company’s financial results on the same day at 4:30 p.m. Eastern Time.

PPHC will also issue its Q3 2026 Results via the London Stock Exchange’s RNS platform at the earliest available opportunity, being 7:00 a.m. GMT on Tuesday, November 10, 2026.

Conference Call Details

Date: Monday, November 9, 2026

Time: 4:30 p.m. Eastern Time

Webcast: Participants may access the conference call via live webcast at https://edge.media-server.com/mmc/p/pkaeo8z7/

Dial-in: To participate via telephone, please register in advance and receive a unique PIN at https://register-conf.media-server.com/register/BI779e286feb6c462e9f64ebe001de757a

A replay of the webcast of the conference call will be available in the Investor Relations section of the Company’s website at investors.pphcompany.com. 

Investor Conference Details

In addition, the Company announced management’s participation during Stephens’ Annual Investment Conference in Nashville, TN being held from Tuesday, November 17 to Thursday, November 19, 2026.

Thomas Gensemer, Chief Strategy Officer, and Matthew Mazzanti, Chief Administrative Officer, will be available for 1×1 meetings with investors throughout the conference.

To schedule a 1×1 meeting with management, please contact your Stephens representative or investor relations at IR@pphcompany.com.

About PPHC

Incorporated in 2014, PPHC is a global strategic communications platform that supports clients in enhancing and defending their reputations, advancing policy objectives, managing regulatory risk, and engaging with federal and state-level policymakers, stakeholders, media, and the public.

Engaged by approximately 1,500 clients, including companies, trade associations and non-governmental organizations, PPHC is active in all major sectors of the economy, including healthcare and pharmaceuticals, financial services, energy, technology, telecommunications and transportation.

With operations across the United States and internationally, PPHC’s services include government relations, public affairs and corporate communications, research and analytics, digital advocacy campaigning, and compliance support. The Company’s shares are admitted to trading on the Nasdaq Global Market and on AIM, a market operated by the London Stock Exchange, under the ticker symbol “PPHC”.

For more information, visit www.pphcompany.com.

Media Contact:

Public Policy Holding Company, Inc.
(202) 688-0020
inquiries@pphcompany.com

Investor Relations:

Public Policy Holding Company, Inc.
(202) 688-0020
IR@pphcompany.com

• Third quarter 2026 earnings per share of $2.09, up 27% year-over-year
• Marine transportation revenues increased 17% year-over-year as market fundamentals continued to improve, driven by strong customer demand
• Distribution and services revenues grew 6% year-over-year, driven by robust demand for behind-the-meter and backup power solutions
• Returned $112 million of capital to shareholders through share repurchases during the third quarter of 2026
• Entered into an agreement to acquire certain inland marine assets from undisclosed sellers for $115 million, including nine inland towboats, 14 inland tank barges, nine bow thrusters, and a fleeting operation serving the Corpus Christi area
• Updated full-year earnings per share growth guidance range of 10% to 15% based on current outlook

HOUSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby” or “the Company”) (NYSE: KEX) today announced net earnings attributable to Kirby for the third quarter ended September 30, 2026, of $110.8 million, or $2.09 per share, compared with earnings of $92.5 million, or $1.65 per share, for the 2025 third quarter. Total revenues for the 2026 third quarter were $977.2 million compared with $871.2 million for the 2025 third quarter.

David Grzebinski, Kirby’s Chief Executive Officer, commented, “Our third quarter results reflected strong continued momentum across both businesses and solid execution throughout the organization. In marine transportation, strong barge utilization and favorable pricing trends supported performance during the quarter, though rising fuel costs continued to impact margins. In distribution and services, results benefited from robust demand in power generation and the strong growth of behind-the-meter solutions. Overall, the company executed well during the quarter and delivered solid financial and operating results, reflecting our continued focus on safety and operational excellence.”

“In inland marine, market fundamentals remained constructive during the quarter. Strong refinery operating rates, healthy petrochemical activity, and limited new industry capacity supported barge utilization in the low-90% range. Spot market rates improved sequentially in the low- to mid-single-digit range during the quarter, and term contract renewals increased in the low-single-digits compared with the prior year. Rising fuel costs remained a near-term headwind as higher costs were mitigated but not fully offset by cost escalators and rate recovery mechanisms in the quarter. Overall, the inland business delivered margins in the 20% range driven by a combination of steady demand, disciplined execution and limited industry capacity additions.”

“In coastal marine, customer demand remained stable with barge utilization in the high-90% range while third quarter coastal revenues increased slightly year-over-year. We had one contract renewal in the third quarter with an increase in the low-double-digit range. Operating margins were in the mid-teens range reflecting market specific dynamics and ongoing cost pressures.”

“In distribution and services, results reflected favorable market conditions for power generation and strong execution by our commercial and operational teams. Third quarter revenues increased 6% year-over-year, driven by strong demand for behind-the-meter and backup power generation solutions and a healthy environment for commercial and industrial.” Mr. Grzebinski concluded.

Segment Results – Marine Transportation
Marine transportation revenues for the 2026 third quarter were $568.7 million compared with $484.9 million for the 2025 third quarter. Operating income for the 2026 third quarter was $111.9 million compared with $88.6 million for the 2025 third quarter. Operating margin for the 2026 third quarter was 20% compared with 18% for the 2025 third quarter.

In inland marine, average barge utilization was in the low-90% range during the third quarter of 2026. Average spot market rates increased in the low- to mid-single-digit range sequentially during the quarter, reflecting improving market fundamentals. Term contract renewals increased in the low-single-digit range on average compared with the prior year. The inland market represented 81% of segment revenues in the third quarter of 2026. Inland operating margins were in the 20% range despite the impact of ongoing fuel cost headwinds.

In coastal marine, market activity remained strong, with barge utilization in the high-90% range. Coastal marine revenues increased slightly year-over-year and operating margins were in the mid-teens range, primarily reflecting fewer shipyard days compared to the second quarter of 2026. Coastal marine had a single term contract renewal in the third quarter with an increase in the low-double-digit range. Coastal marine represented 19% of segment revenues in the third quarter of 2026.

Segment Results – Distribution and Services
Distribution and services revenues for the 2026 third quarter were $408.5 million compared with $386.2 million for the 2025 third quarter. Operating income for the 2026 third quarter was $48.4 million compared with $42.7 million for the 2025 third quarter. Operating margin was 12% for the 2026 third quarter compared with 11% for the 2025 third quarter.

In the power generation market, revenues increased 8% and operating income increased 13% compared with the 2025 third quarter, reflecting continued demand for behind-the-meter and backup power solutions and solid execution even as OEM supply conditions remained dynamic. Order activity continued to strengthen, driven by demand from data center and industrial customers. Power generation represented approximately 46% of segment revenues for the quarter, with operating margins in the low-double-digit range.

In the commercial and industrial market, revenues increased 8% and operating income increased 23% compared with the 2025 third quarter, primarily reflecting strong marine repair activity and healthy demand across other industrial end markets. Commercial and industrial represented approximately 44% of segment revenues for the quarter, with operating margins in the low-double-digit range.

In the oil and gas market, revenues decreased 9% and operating income decreased 15% compared with the 2025 third quarter; however, revenues were flat and operating income was up 54% sequentially driven by higher-margin parts and service activity and ongoing cost management. Oil and gas revenues represented approximately 10% of segment revenues for the quarter, with operating margins in the low-double-digit range.

Acquisition of Inland Marine Assets
During the third quarter, Kirby entered into an agreement to acquire certain inland marine assets from undisclosed sellers for $115 million. The acquisition includes nine inland towboats, fourteen inland tank barges, nine bow thrusters, and a fleeting operation in Rockport, Texas, which is located on a 65-acre facility serving the Corpus Christi area. The acquired assets will enhance Kirby’s inland marine network in South Texas, expand fleeting and fueling capabilities near Corpus Christi, and support continued demand in the West End linehaul system. The transaction is expected to close in the fourth quarter of 2026 subject to customary closing conditions.

Financial Highlights
For the 2026 third quarter, EBITDA (non-GAAP) was $229.7 million compared with $201.4 million for the 2025 third quarter. During the quarter, net cash provided by operating activities was $143.5 million, and capital expenditures were $69.5 million, resulting in free cash flow (non-GAAP) of $74.0 million. Working capital remained elevated during the quarter, reflecting higher revenues in both segments, timing of collections, and higher fuel-related receivables in marine transportation.

In the 2026 third quarter, Kirby returned $112 million of capital through share repurchases at an average share price of $137.04. As of September 30, 2026, the Company had $38.3 million of cash and cash equivalents and $530 million of liquidity available. Total debt was $1,072 million and the debt-to-capitalization ratio was 23.7%.

2026 Outlook
Commenting on the outlook for the fourth quarter of 2026, Mr. Grzebinski stated, “As we enter the fourth quarter of 2026, we remain encouraged by the momentum across our businesses. Driven by strong operational execution and favorable market conditions, we believe Kirby is well positioned to capitalize on opportunities across our end markets and deliver solid performance in the remainder of the year. Despite ongoing macroeconomic and geopolitical uncertainty, customer demand remains healthy across many of our end markets. Based on current market conditions, we are narrowing our full-year earnings per share growth guidance to 10% to 15% and currently expect results toward the upper end of the range.”

In inland marine, market fundamentals are expected to remain constructive, supported by robust supply-demand dynamics and strong refinery and petrochemical operating rates. Barge utilization is expected to remain in the low-90% range, while both spot pricing and term contract renewal rates are expected to improve further during the remainder of the year. Inland operating conditions are expected to reflect normal seasonal weather impacts during the fourth quarter. Overall, inland revenues are expected to grow in the low-double-digit range, with operating margins expected to be in the high-teens to low-20% range for the full year.

In coastal marine, customer demand remains stable with barge utilization expected to remain in the high-90% range. Overall market conditions remain constructive, and pricing trends continue to improve, although elevated planned shipyard activity and higher fuel costs are expected to pressure margins during the fourth quarter. Overall, revenues are expected to increase in the mid-to-high-single-digit range for the full year, with operating margins expected to be in the mid-teens range.

In distribution and services, continued growth in power generation and strong marine repair activity are expected to support full-year results. In power generation, order momentum remains strong, supported by data center demand and the need for behind-the-meter and backup power solutions. While OEM engine delivery timing continues to create some variability in quarterly results, underlying customer demand remains robust. In commercial and industrial, customer activity is expected to remain healthy driven by strong demand in marine repair. In oil and gas, activity is expected to remain stable, subject to changes in the market environment. Overall, the Company expects segment revenues to grow in the high-single-digit range for the full year, with operating margins in the high-single-digit range.

The Company expects to generate net cash provided by operating activities of $575 million to $675 million in 2026 and capital spending is expected to range from $220 million to $260 million. Approximately $170 million to $210 million is expected to be allocated to marine maintenance capital and improvements to existing inland and coastal marine equipment, and facility improvements. Up to approximately $65 million is expected to be allocated to growth capital spending across both of our businesses.

Conference Call
A conference call is scheduled for 7:30 a.m. Central Daylight Time today, October 28, 2026, to discuss the 2026 third quarter performance as well as the outlook for 2026. To listen to the webcast, please visit the Investor Relations section of Kirby’s website at www.kirbycorp.com. For listeners who wish to participate in the question and answer session via telephone, please pre-register at Kirby Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. A slide presentation for this conference call will be posted on Kirby’s website approximately 15 minutes before the start of the webcast. A replay of the webcast will be available for a period of one year by visiting the News & Events page in the Investor Relations section of Kirby’s website.

GAAP to Non-GAAP Financial Measures
The financial and other information to be discussed in the conference call is available in this press release and in a Form 8-K filed with the Securities and Exchange Commission. This press release and the Form 8-K includes a non-GAAP financial measure, EBITDA, which Kirby defines as net earnings attributable to Kirby before interest expense, taxes on income, and depreciation and amortization. A reconciliation of EBITDA with GAAP net earnings attributable to Kirby is included in this press release. This press release also includes non-GAAP financial measures which exclude certain one-time items, including earnings before taxes on income (excluding one-time items), net earnings attributable to Kirby (excluding one-time items), and diluted earnings per share (excluding one-time items). A reconciliation of these measures with GAAP is included in this press release. Management believes the exclusion of certain one-time items from these financial measures enables it and investors to assess and understand operating performance, especially when comparing those results with previous and subsequent periods or forecasting performance for future periods, primarily because management views the excluded items to be outside of Kirby’s normal operating results. This press release additionally includes a non-GAAP financial measure, free cash flow, which Kirby defines as net cash provided by operating activities less capital expenditures. A reconciliation of free cash flow with GAAP is included in this press release. Kirby uses free cash flow to assess and forecast cash flow and to provide additional disclosures on the Company’s liquidity. Free cash flow does not imply the amount of residual cash flow available for discretionary expenditures as it excludes mandatory debt service requirements and other non-discretionary expenditures. This press release also includes marine transportation performance measures, consisting of ton miles, revenue per ton mile, towboats operated and delay days. Comparable marine transportation performance measures for the 2025 year and quarters are available in the Investor Relations section of Kirby’s website, www.kirbycorp.com, under Financials.

Forward-Looking Statements
Statements contained in this press release with respect to the future are forward-looking statements. These statements reflect management’s reasonable judgment with respect to future events. Forward-looking statements involve risks and uncertainties. Actual results could differ materially from those anticipated as a result of various factors, including adverse economic conditions, industry competition and other competitive factors, adverse weather conditions such as high water, low water, tropical storms, hurricanes, tsunamis, fog and ice, tornados, marine accidents, lock delays, fuel costs, interest rates, construction of new equipment by competitors, government and environmental laws and regulations, and the timing, magnitude and number of acquisitions made by the Company. Forward-looking statements are based on currently available information and Kirby assumes no obligation to update any such statements. A list of additional risk factors can be found in Kirby’s annual report on Form 10-K for the year ended December 31, 2025 and quarterly report on Form 10-Q for the quarter ended June 30, 2026.

About Kirby Corporation
Kirby Corporation, based in Houston, Texas, is the nation’s largest domestic tank barge operator, transporting bulk liquid products throughout the Mississippi River System, on the Gulf Intracoastal Waterway, and coastwise along all three United States coasts. Kirby transports petrochemicals, black oil, refined petroleum products, and agricultural chemicals by tank barge. In addition, Kirby participates in the transportation of dry-bulk commodities in United States coastwise trade. Through the distribution and services segment, Kirby provides equipment, after-market parts and services for power generation systems in applications that include behind the meter power systems and emergency backup systems, after-market and genuine replacement parts and services for engines, transmissions, reduction gears, electric motors, drives, and controls, specialized electrical distribution and controls systems, and related equipment used in power generation, marine, on-highway, oilfield services, and other industrial applications. Kirby also rents equipment including generators, industrial compressors, high-capacity lift trucks, construction equipment, and refrigeration trailers for use in a variety of industrial markets. Kirby also manufactures and remanufactures specialized equipment, including pressure pumping units and electric fracturing systems, electric power generation equipment, and specialized electrical distribution and control equipment for data centers, oilfield service, railroad, and other industrial customers.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
		Third Quarter								Nine Months
		2026				2025				2026				2025
		(unaudited, $ in thousands, except per share amounts)
Revenues:
Marine transportation		$	568,725			$	484,941			$	1,602,882			$	1,453,652
Distribution and services			408,482				386,220				1,140,823				1,058,623
Total revenues			977,207				871,161				2,743,705				2,512,275
Costs and expenses:
Costs of sales and operating expenses			651,342				580,491				1,841,470				1,656,065
Selling, general and administrative			92,499				87,812				282,468				268,945
Taxes, other than on income			10,062				9,768				29,995				29,140
Depreciation and amortization			71,580				66,873				210,179				196,273
(Gain) loss on disposition of assets			813				(3,002	)			(1,348	)			(4,759	)
Total costs and expenses			826,296				741,942				2,362,764				2,145,664
Operating income			150,911				129,219				380,941				366,611
Other income			7,261				5,557				21,569				15,703
Interest expense			(11,269	)			(11,838	)			(32,496	)			(35,105	)
Earnings before taxes on income			146,903				122,938				370,014				347,209
Provision for taxes on income			(35,994	)			(30,200	)			(87,981	)			(83,823	)
Net earnings			110,909				92,738				282,033				263,386
Net earnings attributable to noncontrolling interests			(94	)			(242	)			(292	)			(627	)
Net earnings attributable to Kirby		$	110,815			$	92,496			$	281,741			$	262,759
Net earnings per share attributable to Kirby common stockholders:
Basic		$	2.10			$	1.66			$	5.29			$	4.67
Diluted		$	2.09			$	1.65			$	5.26			$	4.64
Common stock outstanding (in thousands):
Basic			52,690				55,626				53,234				56,212
Diluted			53,019				55,970				53,568				56,560

CONDENSED CONSOLIDATED FINANCIAL INFORMATION
		Third Quarter								Nine Months
		2026				2025				2026				2025
		(unaudited, $ in thousands)
EBITDA:(1)
Net earnings attributable to Kirby		$	110,815			$	92,496			$	281,741			$	262,759
Interest expense			11,269				11,838				32,496				35,105
Provision for taxes on income			35,994				30,200				87,981				83,823
Depreciation and amortization			71,580				66,873				210,179				196,273
		$	229,658			$	201,407			$	612,397			$	577,960
Capital expenditures		$	69,531			$	67,280			$	189,295			$	217,440
Acquisitions of businesses and marine equipment		$	—			$	9,200			$	95,800			$	106,450

		September 30, 2026				December 31, 2025
		(unaudited, $ in thousands)
Cash and cash equivalents		$	38,290			$	78,775
Long-term debt, including current portion		$	1,071,751			$	919,281
Total equity		$	3,443,292			$	3,382,793
Debt to capitalization ratio			23.7	%			21.4	%

MARINE TRANSPORTATION STATEMENTS OF EARNINGS
		Third Quarter								Nine Months
		2026				2025				2026				2025
		(unaudited, $ in thousands)
Marine transportation revenues		$	568,725			$	484,941			$	1,602,882			$	1,453,652
Costs and expenses:
Costs of sales and operating expenses			353,991				300,021				1,003,280				889,797
Selling, general and administrative			36,663				34,985				115,927				108,854
Taxes, other than on income			7,597				7,266				22,816				21,842
Depreciation and amortization			58,564				54,100				171,492				158,954
Total costs and expenses			456,815				396,372				1,313,515				1,179,447
Operating income		$	111,910			$	88,569			$	289,367			$	274,205
Operating margin			19.7	%			18.3	%			18.1	%			18.9	%

DISTRIBUTION AND SERVICES STATEMENTS OF EARNINGS
		Third Quarter								Nine Months
		2026				2025				2026				2025
		(unaudited, $ in thousands)
Distribution and services revenues		$	408,482			$	386,220			$	1,140,823			$	1,058,623
Costs and expenses:
Costs of sales and operating expenses			296,861				280,049				836,859				766,608
Selling, general and administrative			50,014				50,081				154,516				152,154
Taxes, other than on income			2,438				2,472				7,105				7,216
Depreciation and amortization			10,745				10,949				32,422				31,950
Total costs and expenses			360,058				343,551				1,030,902				957,928
Operating income		$	48,424			$	42,669			$	109,921			$	100,695
Operating margin			11.9	%			11.0	%			9.6	%			9.5	%

OTHER COSTS AND EXPENSES
		Third Quarter								Nine Months
		2026				2025				2026				2025
		(unaudited, $ in thousands)
General corporate expenses		$	8,610			$	5,021			$	19,695			$	13,048
(Gain) loss on disposition of assets		$	813			$	(3,002	)		$	(1,348	)		$	(4,759	)

RECONCILIATION OF FREE CASH FLOW

The following is a reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow⁽²⁾:

		Third Quarter								Nine Months
		2026				2025(3)				2026				2025(3)
		(unaudited, $ in millions)
Net cash provided by operating activities		$	143.5			$	227.5			$	313.4			$	358.0
Less: Capital expenditures			(69.5	)			(67.2	)			(189.3	)			(217.4	)
Free cash flow(2)		$	74.0			$	160.3			$	124.1			$	140.6

MARINE TRANSPORTATION PERFORMANCE MEASUREMENTS
		Third Quarter								Nine Months
		2026				2025				2026				2025
Inland Performance Measurements:
Ton Miles (in millions)(4)			4,183				3,497				11,831				10,485
Revenue/Ton Mile (cents/tm)(5)			11.0				10.8				10.9				11.1
Towboats operated (average)(6)			294				270				290				283
Delay Days(7)			1,809				1,442				7,640				8,791
Average cost per gallon of fuel consumed		$	3.91			$	2.46			$	3.49			$	2.46
Barges (active):
Inland tank barges											1,148				1,105
Coastal tank barges											27				28
Offshore dry-cargo barges											2				2
Barrel capacities (in millions):
Inland tank barges											25.7				24.5
Coastal tank barges											2.9				2.9

1. Kirby has historically evaluated its operating performance using numerous measures, one of which is EBITDA, a non-GAAP financial measure. Kirby defines EBITDA as net earnings attributable to Kirby before interest expense, taxes on income, and depreciation and amortization. EBITDA is presented because of its wide acceptance as a financial indicator. EBITDA is one of the performance measures used in calculating performance compensation pursuant to Kirby’s annual incentive plan. EBITDA is also used by rating agencies in determining Kirby’s credit rating and by analysts publishing research reports on Kirby, as well as by investors and investment bankers generally in valuing companies. EBITDA is not a calculation based on generally accepted accounting principles and should not be considered as an alternative to, but should only be considered in conjunction with, Kirby’s GAAP financial information.
2. Kirby uses certain non-GAAP financial measures to review performance excluding certain one-time items including: earnings before taxes on income, excluding one-time items; net earnings attributable to Kirby, excluding one-time items; and diluted earnings per share, excluding one-time items. Management believes the exclusion of certain one-time items from these financial measures enables it and investors to assess and understand operating performance, especially when comparing those results with previous and subsequent periods or forecasting performance for future periods, primarily because management views the excluded items to be outside of the company’s normal operating results. Kirby also uses free cash flow, which is defined as net cash provided by operating activities less capital expenditures, to assess and forecast cash flow and to provide additional disclosures on the Company’s liquidity. Free cash flow does not imply the amount of residual cash flow available for discretionary expenditures as it excludes mandatory debt service requirements and other non-discretionary expenditures. These non-GAAP financial measures are not calculations based on generally accepted accounting principles and should not be considered as an alternative to but should only be considered in conjunction with Kirby’s GAAP financial information.
3. See Kirby’s annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended September 30, 2025 for amounts provided by (used in) investing and financing activities.
4. Ton miles indicate fleet productivity by measuring the distance (in miles) a loaded tank barge is moved. Example: A typical 30,000 barrel tank barge loaded with 3,300 tons of liquid cargo is moved 100 miles, thus generating 330,000 ton miles.
5. Inland marine transportation revenues divided by ton miles. Example: Third quarter 2026 inland marine transportation revenues of $460.1 million divided by 4,183 million inland marine transportation ton miles = 11.0 cents.
6. Towboats operated are the average number of owned and chartered towboats operated during the period.
7. Delay days measures the lost time incurred by a tow (towboat and one or more tank barges) during transit. The measure includes transit delays caused by weather, lock congestion and other navigational factors.

Contact:
Donny Chia
713-435-1077

Drilling highlights include 5.32 g/t Au over 2.5 metres and 3.03 g/t Au over 4.6 metres

BROSSARD, Quebec, Oct. 28, 2026 (GLOBE NEWSWIRE) — VIOR GOLD CORPORATION INC. (“Vior Gold Corporation”, “Vior” or the “Corporation”) (TSXV: VIO, OTCQB: VIORF, FRA: VL5) is pleased to report initial drill results from the Kinebik project, located approximately 40 km north of the town of Lebel-sur-Quevillon, Eeyou Istchee Baie James, Quebec. The Kinebik project is subject to an Asset Purchase Agreement with Agnico Eagle Mines Limited (“Agnico Eagle”), dated March 4, 2026, pursuant to which Vior has the right to acquire a 100% interest in the Project upon completion of the transaction (See news release dated March 5, 2026).

Highlights

• Drill hole KN-26-002 returned 3.03 g/t Au over 4.6 metres at a depth of 709.4 metres, representing the deepest gold intersection reported to date at Cameron Main.
• Drill hole KN-26-008 intersected 5.32 g/t Au over 2.5 metres at a shallow depth of 88.0 metres as well as 2.23 g/t Au over 5.1 metres, confirming the western extension of the Florence gold structure.
• Drill hole KN-26-016 intersected 2.01 g/t Au over 8.8 metres within a strongly silica-altered brecciated granodiorite intrusion, outlining a previously unrecognized style of mineralization at Florence.
• This news release reports results for 1,525 samples received from the laboratory, while assays for 6,359 Kinebik samples remain pending.

Mathieu Savard, President and Chief Executive Officer of Vior Gold Corporation, commented: “We are pleased with these initial results. Long before the March 5, 2026 announcement, we have recognized that Kinebik represented a significant district-scale opportunity that remained largely underexplored despite its highly prospective geological setting. Today’s results from the Cameron Main and Florence areas demonstrate the presence of a very active gold system, with mineralization occurring across multiple lithologies associated with extensive alteration halos. We are particularly excited by the silica breccia intersected in hole KN-26-016. Hosted within a granodiorite intrusion, the interval returned 2.01 g/t Au over 8.8 metres. Mineralization at both Cameron Main and Florence remains open in all directions, highlighting the project’s significant exploration potential. These results support our view that Kinebik has the potential to host a large-scale gold system.

In the meantime, our primary focus remains at Ligneris, where we continue the drilling campaign with 1,500 metres left in the 2026 program. We also have approximately 2,300 assay results pending from the laboratory. We expect to deliver results during November.”

Florence Area

Notable results reported in this news release include 2.01 g/t Au over 8.8 metres from hole KN-26-016. Mineralization occurs as 1% to 5% pyrite hosted within a strongly sheared, silica-altered, and brecciated granodiorite intrusion. This style of gold mineralization had not previously been recognized at Florence and remains open in all directions.

Drill hole KN-26-008 returned 5.32 g/t Au over 2.5 metres, including 19.2 g/t Au over 0.6 metres at a downhole depth of 88.0 metres. Mineralization consists of trace amounts to locally 15% pyrite occurring as disseminated to semi-massive sulphides within a strongly deformed magnetite-altered basalt.

A second mineralized interval encountered deeper in the hole at 205.4 metres returned 2.23 g/t Au over 5.1 metres within a broader interval grading 1.06 g/t Au over 16.5 metres. Mineralization consists of trace to 5% disseminated pyrite, 1% to 2% pyrrhotite, up to 1% sphalerite in stringers, and traces of chalcopyrite, hosted within basalt intruded by quartz-carbonate-albite injections. Between eight and ten visible gold specks were observed throughout the interval. Hole KN-26-008 is located approximately 80 metres west of historical hole H-1425-066, which returned 2.62 g/t Au over 3.8 metres (from SIGEOM; GM47626). This gold-bearing structure remains open to the west and at depth, as no historical drilling has tested its extensions in those directions.

Cameron Main Area

Drill hole KN-26-002 returned 3.03 g/t Au over 4.6 metres within a silica-altered, strongly sheared basalt, characterized by local hematite banding and crosscut by quartz-carbonate extensional and shear veins. Mineralization within the interval consists of 5% to 10% pyrite, occurring as disseminated and locally as stringers. This interval was intersected at a vertical depth of approximately 590 metres and represents the deepest gold intersection reported to date at Cameron Main. No drilling has been completed in the immediate vicinity of this intercept, underscoring the upside potential of the Cameron system at depth.

Between July 16 and September 19, 2026, Vior completed a total of 8,596 metres on the Kinebik project, including 5,367 metres on Cameron Main and 3,229 metres at Florence. As of October 28, 2026, a total of 1,525 samples has been received from the laboratory, while 6,359 samples remain pending, representing approximately 80% of all submitted samples.

Upon completion of the Asset Purchase Agreement with Agnico Eagle (see news release dated March 5, 2026), which is expected before the end of 2027, Vior will hold a 100% interest in the Kinebik, Peacock, and Launay projects.

Table 1 – Drill Core Assay Results

Drill hole Number	Interval From (m)	Interval To (m)	Interval Width (m)	Au (g/t) Uncut	Area
KN-26-001	337.6	339.4	1.8	4.92	Cameron Main
KN-26-002	709.4	714.0	4.6	3.03	Cameron Main
KN-26-004	242.6	245.1	2.5	2.43	Cameron Main
KN-26-008	88.0	90.5	2.5	5.32	Florence
including	88.0	88.6	0.6	19.2
KN-26-008	205.4	210.5	5.1	2.23	Florence
KN-26-014	618.9	619.4	0.5	13.3	Cameron Main
KN-26-016	349.2	358.0	8.8	2.01	Florence

Table 2 – Drill Hole Collar Locations

Drill hole Number	Azimuth (°)	Dip (°)	Drill Hole Length (m)	UTM Easting	UTM Northing
KN-26-001	200	-45	491	362031.24	5462956.00
KN-26-002	201	-60	888	362161.35	5462999.69
KN-26-004	204	-53	441	362098.55	5462755.81
KN-26-008	14	-52	394	357028.55	5467011.18
KN-26-014	202	-65	723	361646.74	5463097.80
KN-26-016	180	-55	726	357583.00	5467501.00

Quality Control

True widths are estimated at 65-80% of the reported core length intervals. Assays are uncut except where indicated. All NQ core assays reported were obtained by either 1-kg screen fire assay or standard 50-gram fire assay with an AA finish or gravimetric finish at ALS Laboratories in Val d’Or, Québec, or Sudbury, Ontario. The 1-kg screen assay method is used when samples contain coarse gold intervals. Selected samples are also analyzed for multiple elements using a four-acid digestion ICP-MS method at ALS Laboratories. Drill program design, Quality Assurance/Quality Control (“QA/QC”), and interpretation of results are performed by qualified persons employing a QA/QC program consistent with NI 43-101 and industry best practices. Standards and blanks are inserted alternately every 10 samples to adhere to strict QA/QC guidelines and protocols by the Corporation and the lab. Historical results on the Kinebik Project described in this news release are from public sources and the Qualified Person responsible for the review and approval of the technical information disclosed in this news release (see details below) has not verified the information relating to these historical results. Consequently, such information is not necessarily indicative of mineralization on the Kinebik Project.

Qualified Person

The technical content disclosed in this news release was reviewed and approved by Pascal Simard, Vice-President Exploration at Vior Gold Corporation, a Qualified Person under NI 43-101.

About Vior Gold Corporation Inc.

Vior Gold Corporation is a junior mineral exploration corporation based in the province of Quebec, Canada, whose corporate strategy is to generate, explore, and develop high-quality precious metals projects in the proven and favorable mining jurisdiction of Quebec. Through the years, the Corporation’s management and technical teams have demonstrated their ability to discover several multimillion-ounce gold deposits in Quebec.

For further information, please contact:

Mathieu Savard
President and CEO
418-670-1448
msavard@vior.ca

www.vior.ca
SEDAR+: Vior Gold Corporation Inc.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements include, but are not limited to, statements with respect to the closing of the property acquisitions, the ability to obtain the required approvals of the TSX Venture Exchange, the significance of the Corporation’s expansion of the Ligneris and Kinebik district, the Corporation’s planned exploration activities and long-term objectives, the potential of the Ligneris and Kinebik properties, the ability of exploration (including drilling) to accurately predict mineralization, production being achieved at any of the Corporation’s properties, the significance of previous exploration results at the Ligneris and Kinebik properties, and the Corporation’s ability to deliver returns to its shareholders and long-term benefits to its stakeholders. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Corporation, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Corporation nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Corporation does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/9f3c9bce-503f-470d-9888-1d569656d59e

TORONTO, Oct. 28, 2026 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (“Dundee” or the “Corporation”) is pleased to report additional high-grade infill results from the South Zone at the Shovelnose Gold Project, including 23 meters grading 6.69g/t gold and 41.7g/t silver.

With the 117 hole resource infill program now complete, six drills remain active at Shovelnose as the project moves into its next phase. Work is focused on a broader exploration program together with the geotechnical and hydrogeological drilling required to support the South Zone pre-feasibility study targeted for completion in the second half of 2027.

Jonathan Goodman, President and CEO commented:

“This is an exciting transition point for Shovelnose. We have completed the resource infill drilling and are now focused on two important priorities: stepping out to test the broader exploration potential of the property as well as completing the field work required to advance the South Zone pre-feasibility study. With six drills active, we are continuing to build momentum both around the existing resource while testing the much larger potential of the property.”

Key Highlights:

• New South Zone infill drill results include highlight assays of:
  • 23.00m grading 6.69 g/t Au and 41.7 g/t Ag
  • 5.53m grading 16.51 g/t Au and 133.5 g/t Ag
  • 14.59m grading 4.38 g/t Au and 27.6 g/t Ag
  • 10.30m grading 3.51 g/t Au and 23.5 g/t Ag
  • 6.04m grading 5.79 g/t Au and 3.5 g/t Ag
  • 16.41m grading 2.07 g/t Au and 23.2 g/t Ag
  • 5.97m grading 5.34 g/t Au and 10.6 g/t Ag
  • 1.5m grading 20.90 g/t Au and 29.1 g/t Ag
  • 6.07m grading 4.56 g/t Au and 7.6 g/t Ag
• Approximately 10,000m of exploration, hydrogeological and geotechnical drilling has been completed to date, including 10 exploration drill holes testing areas below and to the north of the South Zone deposit (5,008m). Exploration drilling is expected to continue through to December 15, 2026.
• Ongoing geotechnical and hydrogeology drilling programs supporting the South Zone PFS are on track for completion in Q4 2026.

On February 23, 2026, the Corporation completed a strategic earn-in agreement with Westhaven, whereby Dundee may earn up to a 60% interest in Westhaven’s four Spences Bridge Gold Belt properties through up to CDN$85,000,000 in staged project expenditures. Under the first phase, Dundee has committed a minimum of CDN$30,000,000, inclusive of a fully funded 50,000m drill program at Shovelnose, which is funding the activities outlined in this news release and is expected to continue through the remainder of 2026.

South Zone Mineral Resource Infill Drilling

Assay results from the 117-hole (37,242m) resource infill drill program at the South Zone deposit continue to show excellent continuity of mineralization in each of Vein Zones 1, 2 and 3. Results have been received from an additional 19 infill drill holes and are reported in Table 1, bringing the total number of reported drillholes to 91. For previously reported assay results from the South Zone mineral resource drilling program, please refer to the Corporation’s press releases dated May 7, 2026, May 26, 2026, July 7, 2026, July 28, 2026, August 20, 2026, and September 22, 2026. The resource drilling program was designed to infill the deposit at nominal 25m centres with results to be included in an updated mineral resource estimate to support a PFS targeting completion in H2 2027.

Selected assay highlights include:

SNR26-123:	14.59m grading 4.38 g/t Au & 28 g/t Ag from 313.40m downhole
SNR26-125:	3.00m grading 5.93 g/t Au & 7 g/t Ag from 116.00m downhole; and
	5.53m grading 16.51 g/t Au & 134 g/t Ag from 163.00m downhole
SNR26-127:	10.30m grading 3.51 g/t Au & 24 g/t Ag from 143.50m downhole; and
	6.04m grading 5.79 g/t Au & 4 g/t Ag from 182.90m downhole; and
	6.00m grading 3.17 g/t Au & 5 g/t Ag from 229.00m downhole
SNR26-137b:	16.41m grading 2.07 g/t Au & 23 g/t Ag from 264.59m downhole
SNR26-140:	1.50m grading 20.90 g/t Au & 29 g/t Ag from 265.50m downhole; and
	5.28m grading 2.31 g/t Au & 10 g/t Ag from 377.38m downhole
SNR26-149:	2.72m grading 2.29 g/t Au & 7 g/t Ag from 152.28m downhole; and
	2.29m grading 3.07 g/t Au & 4 g/t Ag from 182.00m downhole; and
	23.00m grading 6.69 g/t Au & 42 g/t Ag from 193.00m downhole
SNR26-150:	5.97m grading 5.34 g/t Au & 11 g/t Ag from 76.64m downhole
SNR26-157:	6.07m grading 4.56 g/t Au & 8 g/t Ag from 147.13m downhole

Table 1 shows assay results, including drill hole locations and orientations. Reported assay intervals represent downhole intersections, not true widths. True widths can be estimated at approximately 70-80% of the reported intervals.

Figure 1 shows the locations of the drill holes reported in this news release, as well as the other holes completed in 2026, the remaining planned 2026 drill collar locations and the drill collars of pre-2026 drilling of the South Zone.

Figure 2 presents a South Zone cross-section highlighting drill hole SNR26-149, and the sections are viewed to the northwest (310°) and illustrate strong continuity of mineralization hosted within structurally controlled quartz veins and hydrothermal breccia zones.

Sampling, Laboratory Analyses and Quality Assurance/Quality Control (QA/QC)

Most core samples consist of halved drill core cut by manual sawing using industry standard core saws. In rare cases, and where required by physical core conditions, manual splitting may be used. Half of the core is retained in the original core box for reference samples and any required future work, including QA/QC. Core samples, controlled by a unique bar-coded reference number, are delivered to ALS’s Kamloops facility and prepared using the PREP-31 package. Each core sample is crushed to better than 70% passing a 2mm (Tyler 9 mesh, US Std. No.10) screen. A split of 250g is taken and pulverized to better than 85% passing a 75-micron (Tyler 200 mesh, US Std. No. 200) screen.

Further analytical and assay procedures are conducted in ALS’s North Vancouver facility. A 0.75g subsample of the pulverized split is subjected to four acid digestion and analyzed via ICP-MS (method code ME-MS61m (+Hg)) which reports a suite of 49 elements.

All samples are also analyzed for gold by fire assay with an AES finish, method code Au-ICP21 (30g sample size) or Au-ICP22 (50g sample size). Samples returning gold values over 10ppm are subjected to over-limit check assays using fire assay and a gravimetric finish (method code Au-GRA21 and a 30g sample size, or Au-GRAV22 and a 50g sample size). The switch to 50g aliquots applies to 2026 resource infill drill holes starting at, and including, SNR26-98. Other over-limit elements may also be subjected to ore grade analyses which vary depending on the element of interest.

ALS’s facilities are accredited to the ISO/IEC 17025 standard for gold assays, and all analytical methods include quality control materials at set frequencies with established data acceptance criteria.

QA/QC incorporates the laboratory’s internal quality assurance controls as well as Westhaven’s field controls, including the insertion of quarter core duplicates, certified reference materials and blanks, each at a rate of roughly one per 20-25 core samples.
Additional blanks are inserted following samples with visible gold or significant concentrations of ginguro (fine grained bands of dark gray to black sulphides).

QA/QC data are evaluated on receipt for failures, and appropriate action is taken if results for duplicates, standards and blanks fall outside allowed tolerances. Westhaven’s ongoing QA/QC programs are consistent with industry best practices and include auditing of all exploration data. Any significant changes will be reported when available.

Figure 1 – Plan View Map October 2026

Figure 2 – South Zone Cross Section A-A’

Table 1 – Assay Highlights

ABOUT DUNDEE CORPORATION:

Dundee Corporation is a public Canadian independent mining-focused holding company, listed on the Toronto Stock Exchange under the symbol “DC.A”. The Corporation is primarily engaged in acquiring mineral resource assets. The Corporation operates with the objective of unlocking value through strategic investments in mining projects globally. Our team conducts due diligence in order to assess the geological, technical, environmental, and financial merits and risks of each project and looks to deploy capital where it can either seek to generate investment returns or where the Corporation can collaborate with operating partners and take strategic partnerships through direct interests in mining operations.

Qualified Person

The scientific and technical information in this news release has been reviewed and approved by Robin Hopkins, P.Geo. (NT/NU), Vice President, Exploration for Westhaven and a Qualified Person for Westhaven under the definitions established by National Instrument 43-101 Standards of Disclosure for Mineral Projects. Mr. Hopkins is independent of Dundee.

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor and Media Relations
T: (416) 864-3584
E: ir@dundeecorporation.com

FORWARD-LOOKING STATEMENTS:

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. These forward-looking statements are made as of the date of this news release and Dundee does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law.

Forward-looking statements in this news release may include, but are not limited to, statements with respect to completing approximately 50,000m of drilling during the year; completing an updated South Zone mineral resource estimate and the planned Pre-Feasibility Study; future planned activities; future mineral production and future growth potential for the Shovelnose project; the interpretation of preliminary results from exploration undertaken to date at the Shovelnose project using various exploration techniques and analysis; statements with respect to potential styles of epithermal mineralization at the Shovelnose project; and, the possibility that the Shovelnose project may host multiple gold bearing epithermal systems.

In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are based on the opinions and estimates of management of Dundee as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Assumptions have been made regarding, among other things, the price of gold and other precious metals; costs of exploration and development; the estimated costs of development of Shovelnose; Westhaven’s ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

Although management of Dundee have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Many factors, both known and unknown, could cause actual results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information. Such factors include, without limitation: precious metals price volatility; regulatory, consent or permitting delays; risks relating to reliance on Westhaven’s management team and outside contractors; risks regarding mineral resources and reserves; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; laws and regulations governing the environment, health and safety; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; Westhaven’s interactions with surrounding communities; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; and the factors identified in Dundee’s other public disclosure available on SEDAR+ at www.sedarplus.ca. Mineral exploration involves a high degree of risk and few properties, which are explored, are ultimately developed into producing mines. There can be no assurance that such forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2f9e9461-21ee-4ae9-9106-f980d8eee2cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/4ddcf8a4-eda3-4032-ba4b-76ff8a435417

https://www.globenewswire.com/NewsRoom/AttachmentNg/25490d24-cd07-4a75-bf94-d325a4240506

RIDGEFIELD, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its third quarter ended September 25, 2026.

Financial highlights for the third quarter of 2026:

• Net sales increased 11.2% to $1.14 billion for the third quarter of 2026 from $1.02 billion for the third quarter of 2025.
• GAAP net income was $29.6 million, or $0.67 per diluted share, for the third quarter of 2026 compared to $19.1 million, or $0.44 per diluted share, in the third quarter of 2025.
• Adjusted net income per share¹ was $0.66 for the third quarter of 2026 compared to $0.50 for the third quarter of 2025.
• Adjusted EBITDA¹ was $82.2 million for the third quarter of 2026 compared to $65.1 million for the third quarter of 2025.

“Revenue trends displayed typical seasonal cadence through the third quarter of 2026, building from the summer months into September with strong year-over-year growth. Our regional Chefs’ Warehouse teams delivered excellent execution across markets and product categories – driving strong growth in revenue and gross profit dollars; as well as continued progress increasing relevance with our customer base with solid year-over-year growth in unique item placements and unique customers. Our Middle East operations continue to operate effectively in a challenging environment. Revenue trends in recent weeks have been approximately 100% of prior-year, as food-away-from-home activity is supported by local residents and ex-patriots returning from the summer off-season”, said Christopher Pappas, Chairman and Chief Executive of the Company. “Momentum continued into October, and as we head into the busy holiday season, I would like to thank all our Chefs’ Warehouse teams, from sales, procurement and operations to all the supporting functions, for their dedication and commitment to delivering our diverse, high-quality product, and service, in partnership with our suppliers and customers and the communities we serve.”

Third Quarter Fiscal 2026 Results

Net sales for the third quarter of 2026 increased 11.2% to $1.14 billion from $1.02 billion in the third quarter of 2025. Organic sales increased $105.4 million, or 10.3% versus the prior year quarter. Sales growth of $8.7 million, or 0.9%, was primarily a result of acquisitions. Organic case count increased approximately 6.1% in the Company’s specialty category for the third quarter of 2026 with unique customer and placement increases of 4.4% and 7.2% respectively, compared to the third quarter of 2025. Organic pounds sold in the Company’s center-of-the-plate category increased approximately 6.6% for the third quarter of 2026 compared to the prior year quarter.

Gross profit increased 15.0% to $284.3 million for the third quarter of 2026 from $247.2 million for the third quarter of 2025. The increase in gross profit dollars was primarily a result of increased sales volumes, price inflation and acquisitions. Gross profit margins increased approximately 84 basis points to 25.0%. Gross profit margins increased 63 basis points in the Company’s specialty category and increased 137 basis points in the center-of-the-plate category.

Selling, general and administrative expenses increased by approximately 12.1% to $233.4 million for the third quarter of 2026 from $208.1 million for the third quarter of 2025. The increase was primarily due to higher costs associated with compensation and benefits, facilities and distribution to support sales growth, fuel costs, as well as higher depreciation expense driven by facility and fleet investments. As a percentage of net sales, selling, general and administrative expenses were 20.6% in the third quarter of 2026 compared to 20.4% in the third quarter of 2025.

Operating income for the third quarter of 2026 was $51.5 million compared to $38.9 million for the third quarter of 2025. The increase in operating income was driven primarily by higher gross profit, partially offset by higher selling, general and administrative expenses, as discussed above. As a percentage of net sales, operating income was 4.4% in the third quarter of 2026 as compared to 3.8% in the third quarter of 2025.

Interest expense decreased to $9.0 million for the third quarter of 2026 compared to $10.5 million for the third quarter of 2025. The decrease was primarily due to lower aggregate principal amounts of debt outstanding and lower interest rates in the current period compared to the prior year quarter.

The Company’s effective tax rate was 30.3% and 32.6% for the third quarters of 2026 and 2025, respectively. The effective rate for the third quarter of 2026 includes a discrete tax benefit related to the vesting of stock awards.

Net income for the third quarter of 2026 was $29.6 million, or $0.67 per diluted share, compared to $19.1 million, or $0.44 per diluted share, for the third quarter of 2025.

Adjusted EBITDA¹ was $82.2 million for the third quarter of 2026 compared to $65.1 million for the third quarter of 2025. For the third quarter of 2026, adjusted net income¹ was $29.5 million, or $0.66 per diluted share compared to adjusted net income of $21.5 million, or $0.50 per diluted share for the third quarter of 2025.

2026 Guidance

We are raising our fiscal 2026 full year financial guidance as follows:

• Net sales in the range of $4.56 billion to $4.61 billion,
• Gross profit to be between $1.130 billion and $1.140 billion and
• Adjusted EBITDA¹ to be between $317 million and $321 million.

Third Quarter 2026 Earnings Conference Call

The Company will host a conference call to discuss third quarter 2026 financial results today at 8:30 a.m. ET. Hosting the call will be Chris Pappas, chairman and chief executive officer, and Jim Leddy, chief financial officer. The conference call will be webcast live from the Company’s investor relations website at http://investors.chefswarehouse.com. An online archive of the webcast will be available on the Company’s investor relations website.

Non-GAAP Financial Measures

We present EBITDA, adjusted EBITDA, adjusted net income and adjusted net income per share, as well as forecasted EBITDA and adjusted EBITDA ranges, which are not measurements determined in accordance with the U.S. Generally Accepted Accounting Principles (“GAAP”), because we believe these measures provide additional metrics to evaluate our operations and our forecasted results and which we believe, when considered with both our GAAP results and the reconciliation to net income and net income available to common shareholders, provide a more complete understanding of our business than could be obtained absent this disclosure. We use EBITDA, adjusted EBITDA, adjusted net income and adjusted net income per share together with financial measures prepared in accordance with GAAP, such as revenue and cash flows from operations, to assess our historical and prospective operating performance and to enhance our understanding of our core operating performance. The use of EBITDA, adjusted EBITDA, adjusted net income and adjusted net income per share as performance measures permits a comparative assessment of our operating performance relative to our GAAP performance while isolating the effects of some items that vary from period to period without any correlation to core operating performance or that vary widely among similar companies.

Other companies may calculate these non-GAAP financial measures differently, and therefore our measures may not be comparable to similarly titled measures of other companies. These non-GAAP financial measures should only be used as supplemental measures of our operating performance.

Please see the schedules accompanying this earnings release for a reconciliation of EBITDA, adjusted EBITDA, adjusted net income and adjusted net income per share to these measures’ most directly comparable GAAP measure.

Forward-Looking Statements

Statements in this press release regarding the Company’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties and are based on current expectations and management estimates; actual results may differ materially. The risks and uncertainties which could impact these statements include, but are not limited to the following: our success depends to a significant extent upon general economic conditions, including disposable income levels and changes in consumer discretionary spending; the relatively low margins of our business, which are sensitive to inflationary and deflationary pressures and intense competition; changes in our credit profile and any effect they may have on our relationships with suppliers; the effects of rising costs for and/or decreases in supply of commodities, ingredients, packaging, other raw materials, distribution and labor; price reductions by our manufacturers of products that we sell which could cause the value of our inventory to decline or our customers to demand lower sales prices; fuel cost volatility and its impact on distribution, packaging and energy costs; our continued ability to promote our brand successfully, to anticipate and respond to new customer demands, and to develop new products and markets to compete effectively; our ability and the ability of our supply chain partners to continue to operate distribution centers and other work locations without material disruption, and to procure ingredients, packaging and other raw materials when needed despite disruptions in the supply chain or labor shortages; risks associated with the expansion of our business; our possible inability to identify new acquisitions or to integrate recent or future acquisitions, or our failure to realize anticipated revenue enhancements, cost savings or other synergies from recent or future acquisitions; other factors that affect the food industry generally, including: recalls if products become adulterated or misbranded, liability if product consumption causes injury, ingredient disclosure and labeling laws and regulations and the possibility that customers could lose confidence in the safety and quality of certain food products; new information or attitudes regarding diet and health or adverse opinions about the health effects of the products we distribute; dependence on independent certifications for products; changes in disposable income levels and consumer purchasing habits; competitors’ pricing practices and promotional spending levels; fluctuations in the level of our customers’ inventories and credit and other related business risks; and the risks associated with third-party suppliers, including the risk that any failure by one or more of our third-party suppliers to comply with food safety or other laws and regulations may disrupt our supply of raw materials or certain products or injure our reputation; our ability to recruit and retain senior management and a highly skilled and diverse workforce; unanticipated expenses, including, without limitation, litigation or legal settlement expenses, adverse judgments, or impairment charges; the cost and adequacy of our insurance policies; the impact and effects of public health crises, pandemics and epidemics and the adverse impact thereof on our business, financial condition, and results of operations; economic and other developments, or events, including adverse weather conditions, in the culinary markets in which we operate; information technology system failures, cybersecurity incidents, or other disruptions to our use of technology and networks; our ability to realize the benefits we anticipate from investments in information technology; our ability to protect our intellectual property; significant governmental regulation and any potential failure to comply with such regulations; changing rules, public disclosure regulations and stakeholder expectations on ESG-related matters; federal, state, provincial and local tax rules in the United States and the foreign countries in which we operate, including tax reform and legislation; climate change, or the legal, regulatory or market measures being implemented to address climate change; the concentration of ownership among our existing executive officers, directors and their affiliates which may prevent new investors from influencing significant corporate decisions; risks relating to our substantial indebtedness; our ability to raise additional capital and/or obtain debt or other financing, on commercially reasonable terms or at all; our ability to meet future cash requirements, including the ability to access financial markets effectively and maintain sufficient liquidity; the effects of currency movements in the jurisdictions in which we operate as compared to the U.S. dollar; and the effects of international trade disputes, tariffs, quotas and other import or export restrictions on our international procurement, sales and operations. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. A more detailed description of these and other risk factors is contained in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026 and other reports filed by the Company with the SEC since that date. The Company is not undertaking to update any information until required by applicable laws. Any projections of future results of operations are based on a number of assumptions, many of which are outside the Company’s control and should not be construed in any manner as a guarantee that such results will in fact occur. These projections are subject to change and could differ materially from final reported results. The Company may from time to time update these publicly announced projections, but it is not obligated to do so.

About The Chefs’ Warehouse

The Chefs’ Warehouse, Inc. (http://www.chefswarehouse.com) is a premier distributor of specialty food products in the United States, the Middle East and Canada focused on serving the specific needs of chefs who own and/or operate some of the nation’s leading menu-driven independent restaurants, fine dining establishments, country clubs, hotels, caterers, culinary schools, bakeries, patisseries, chocolateries, cruise lines, casinos and specialty food stores. The Chefs’ Warehouse, Inc. carries and distributes more than 90,000 products to more than 55,000 customer locations throughout the United States, the Middle East and Canada.

Contact:
Investor Relations
Jim Leddy, CFO, (718) 684-8415

¹ _{Earnings before interest, taxes, depreciation and amortization (“EBITDA”), Adjusted EBITDA, adjusted net income and adjusted net income per share are non-GAAP measures. Please see the schedules accompanying this earnings release for a reconciliation of EBITDA, Adjusted EBITDA, adjusted net income and adjusted net income per share to these measures’ most directly comparable GAAP measure.}

THE CHEFS’ WAREHOUSE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited; in thousands except share amounts and per share data)
		Thirteen Weeks Ended							Thirty-Nine Weeks Ended
		September 25, 2026				September 26, 2025			September 25, 2026				September 26, 2025
Net sales		$	1,135,379			$	1,021,319		$	3,363,002			$	3,006,973
Cost of sales			851,044				774,128			2,528,412				2,279,448
Gross profit			284,335				247,191			834,590				727,525
Selling, general and administrative expenses			233,407				208,125			691,729				624,638
Other operating (income) expenses, net			(558	)			130			(388	)			1,000
Operating income			51,486				38,936			143,249				101,887
Interest expense			8,999				10,535			28,806				31,503
Income before income taxes			42,487				28,401			114,443				70,384
Income tax expense			12,870				9,253			33,692				19,707
Net income		$	29,617			$	19,148		$	80,751			$	50,677
Net income per share:
Basic		$	0.76			$	0.50		$	2.08			$	1.31
Diluted		$	0.67			$	0.44		$	1.83			$	1.18
Numerator:
Net income		$	29,617			$	19,148		$	80,751			$	50,677
Add effect of dilutive securities:
Interest on convertible notes, net of tax			1,175				1,226			3,524				3,677
Net income available to common shareholders		$	30,792			$	20,374		$	84,275			$	54,354
Denominator:
Weighted average basic common shares outstanding			38,814,944				38,575,691			38,852,135				38,717,363
Dilutive effect of unvested common shares and stock options			852,296				729,276			772,396				744,749
Dilutive effect of convertible notes			6,494,970				6,494,970			6,494,970				6,494,970
Weighted average diluted common shares outstanding			46,162,210				45,799,937			46,119,501				45,957,082

THE CHEFS’ WAREHOUSE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited; in thousands)
		September 25, 2026				December 26, 2025
Cash and cash equivalents		$	164,725			$	120,982
Accounts receivable, net			398,827				392,374
Inventories			404,474				385,722
Prepaid expenses and other current assets			73,961				70,811
Total current assets			1,041,987				969,889
Property and equipment, net			353,047				342,019
Operating lease right-of-use assets			196,013				205,270
Goodwill			363,407				362,742
Intangible assets, net			120,649				137,310
Other assets			8,116				10,777
Total assets		$	2,083,219			$	2,028,007
Accounts payable		$	253,871			$	275,622
Accrued liabilities			87,823				78,458
Short-term operating lease liabilities			24,188				24,832
Accrued compensation			73,114				66,350
Current portion of long-term debt			32,105				28,197
Total current liabilities			471,101				473,459
Long-term debt, net of current portion			696,769				720,333
Operating lease liabilities			192,713				201,542
Deferred taxes, net			30,847				22,424
Other liabilities			5,231				5,940
Total liabilities			1,396,661				1,423,698
Common stock			408				407
Additional paid in capital			415,516				405,020
Accumulated other comprehensive loss			(3,341	)			(2,763	)
Retained earnings			273,975				201,645
Stockholders’ equity			686,558				604,309
Total liabilities and stockholders’ equity		$	2,083,219			$	2,028,007

THE CHEFS’ WAREHOUSE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited; in thousands)
		Thirty-Nine Weeks Ended
		September 25, 2026				September 26, 2025
Cash flows from operating activities:
Net income		$	80,751			$	50,677
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property and equipment			45,883				39,045
Amortization of intangible assets			16,624				18,187
Provision for allowance for credit losses			10,013				9,610
Deferred income tax provision			8,366				4,914
Stock compensation			22,123				14,551
Non-cash interest and other operating activities			1,562				5,345
Changes in assets and liabilities, net of acquisitions:
Accounts receivable			(15,723	)			11,327
Inventories			(19,154	)			(70,137	)
Prepaid expenses and other current assets			(5,230	)			(1,085	)
Accounts payable, accrued liabilities and accrued compensation			(4,001	)			(26,825	)
Other liabilities
Other assets and liabilities			(76	)			(257	)
Net cash provided by operating activities			141,138				55,352
Cash flows from investing activities:
Capital expenditures			(25,413	)			(33,340	)
Cash paid for acquisitions, net of cash acquired			(283	)			—
Net cash used in investing activities			(25,696	)			(33,340	)
Cash flows from financing activities:
Payment of debt and other financing obligations			(7,250	)			(12,250	)
Payment of finance leases			(15,935	)			(11,843	)
Common stock repurchases			(10,003	)			(15,005	)
Payment of deferred financing fees			—				(658	)
Proceeds from exercise of stock options			2,041				—
Surrender of shares to pay withholding taxes			(10,455	)			(11,833	)
Payments under asset-based loan facility			(30,000	)			(20,000	)
Excess tax benefits on stock compensation
Net cash used in financing activities			(71,602	)			(71,589	)
Effect of foreign currency translation on cash and cash equivalents			(97	)			(17	)
Net change in cash and cash equivalents			43,743				(49,594	)
Cash and cash equivalents at beginning of period			120,982				114,655
Cash and cash equivalents at end of period		$	164,725			$	65,061

THE CHEFS’ WAREHOUSE, INC. RECONCILIATION OF NET INCOME TO EBITDA AND ADJUSTED EBITDA (unaudited; in thousands)
		Thirteen Weeks Ended							Thirty-Nine Weeks Ended
		September 25, 2026				September 26, 2025			September 25, 2026				September 26, 2025
Net income		$	29,617			$	19,148		$	80,751			$	50,677
Interest expense			8,999				10,535			28,806				31,503
Depreciation and amortization of property and equipment			15,723				13,713			45,883				39,045
Amortization of intangible assets			5,453				6,084			16,624				18,187
Income tax expense			12,870				9,253			33,692				19,707
EBITDA (1)			72,662				58,733			205,756				159,119
Adjustments:
Stock compensation (2)			9,297				4,922			22,123				14,551
Other operating (income) expenses, net (3)			(558	)			130			(388	)			1,000
Duplicate rent (4)			756				1,157			2,871				2,875
Moving expenses (5)			29				111			29				438
Adjusted EBITDA (1)		$	82,186			$	65,053		$	230,391			$	177,983

1. See the “Non-GAAP Financial Measures” section of the press release.
2. Represents non-cash stock compensation expense associated with awards of restricted shares of our common stock and stock options to our key employees and our independent directors.
3. Represents non-cash changes in the fair value of contingent earn-out liabilities related to our acquisitions, non-cash charges related to asset disposals, asset impairments, including intangible asset impairment charges, certain third-party deal costs incurred in connection with our acquisitions or financing arrangements and certain other costs.
4. Represents rent and occupancy costs expected to be incurred in connection with our facility consolidations while we are unable to use those facilities.
5. Represents moving expenses for the consolidation and expansion of several of our distribution facilities.

THE CHEFS’ WAREHOUSE, INC. RECONCILIATION OF NET INCOME TO ADJUSTED NET INCOME AND ADJUSTED NET INCOME PER SHARE (unaudited; in thousands except share amounts and per share data)
		Thirteen Weeks Ended							Thirty-Nine Weeks Ended
		September 25, 2026				September 26, 2025			September 25, 2026				September 26, 2025
Net income		$	29,617			$	19,148		$	80,751			$	50,677
Adjustments to reconcile net income to adjusted net income (1):
Other operating (income) expenses, net (2)			(558	)			130			(388	)			1,000
Duplicate rent (3)			756				1,157			2,871				2,875
Moving expenses (4)			29				111			29				438
Debt modification and extinguishment expenses (5)			—				—			655				525
Tax effect of adjustments (6)			(371	)			909			(2,767	)			(1,355	)
Total adjustments			(144	)			2,307			400				3,483
Adjusted net income (1)		$	29,473			$	21,455		$	81,151			$	54,160
Diluted adjusted net income per common share (1)		$	0.66			$	0.50		$	1.84			$	1.26
Numerator:
Adjusted net income (1)		$	29,473			$	21,455		$	81,151			$	54,160
Add effect of dilutive securities:
Interest on convertible notes, net of tax			1,175				1,226			3,524				3,677
Adjusted net income available to common shareholders		$	30,648			$	22,681		$	84,675			$	57,837
Denominator:
Weighted average basic common shares outstanding			38,814,944				38,575,691			38,852,135				38,717,363
Dilutive effect of unvested common shares and stock options			852,296				729,276			772,396				744,749
Dilutive effect of convertible notes			6,494,970				6,494,970			6,494,970				6,494,970
Weighted average diluted common shares outstanding			46,162,210				45,799,937			46,119,501				45,957,082

1. See the “Non-GAAP Financial Measures” section of the press release.
2. Represents non-cash changes in the fair value of contingent earn-out liabilities related to our acquisitions, non-cash charges related to asset disposals, asset impairments, including intangible asset impairment charges, certain third-party deal costs incurred in connection with our acquisitions or financing arrangements and certain other costs. 
3. Represents rent and occupancy costs expected to be incurred in connection with our facility consolidations while we are unable to use those facilities. 
4. Represents moving expenses for the consolidation and expansion of several of our distribution facilities. 
5. Represents debt modification costs, extinguishment costs and interest expense related to the write-off of certain deferred financing fees related to our credit agreements. 
6. Represents the adjustments to the tax expense values to reflect a normalized annual effective tax rate on adjusted pretax earnings of 31.0% and 28.0% for the third quarters of 2026 and 2025, respectively, and year-to-date periods of 2026 and 2025, respectively.

THE CHEFS’ WAREHOUSE, INC. RECONCILIATION OF ADJUSTED EBITDA GUIDANCE FOR FISCAL 2026 (unaudited; in thousands)
		Low-End Guidance			High-End Guidance
Net income:		$	108,500		$	110,000
Income tax expense			45,000			45,500
Depreciation and amortization of property and equipment			85,000			85,000
Interest expense			45,500			46,500
EBITDA (1)			284,000			287,000
Adjustments:
Stock compensation (2)			29,000			30,000
Duplicate rent (3)			3,500			3,500
Other operating expenses (4)			500			500
Adjusted EBITDA (1)		$	317,000		$	321,000

1. See the “Non-GAAP Financial Measures” section of the press release.
2. Represents non-cash stock compensation expense associated with awards of restricted shares of our common stock and stock options to our key employees and our independent directors.
3. Represents rent and occupancy costs expected to be incurred in connection with our facility consolidations while we are unable to use those facilities.
4. Represents non-cash changes in the fair value of contingent earn-out liabilities related to our acquisitions, non-cash charges related to asset disposals, asset impairments, including intangible asset impairment charges, certain third-party deal costs incurred in connection with our acquisitions or financing arrangements, moving expenses for the consolidation and expansion of several of our distribution facilities and certain other costs.

TUDRIQEV first delivered to patients for advanced melanoma on October 6th

More than 15 institutions have prescribed TUDRIQEV

Management will host a webcast today at 8:00 a.m. ET

WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update.

In early October, the Company announced that TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, is now commercially available in the United States for use in combination with nivolumab for the treatment of adults with advanced melanoma. Healthcare providers began ordering TUDRIQEV for next day delivery immediately upon availability. The Company has more than a year of inventory on hand, produced at its in-house manufacturing facility.

“Melanoma takes nearly 8,500 lives in the U.S. every year, and for patients whose disease progresses after anti-PD-1 therapy, treatment options have been limited. TUDRIQEV is now available to patients in urgent need,” said Sushil Patel, Ph.D., CEO of Replimune. “The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”

Program Highlights & Milestones

TUDRIQEV™ (vusolimogene oderparepvec-wtpg)

• Early launch off to a positive start. The Company has actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable TUDRIQEV adoption. Leading melanoma institutions have rapidly placed TUDRIQEV on formulary and have started treating patients.
• Broad label supports use across a wide range of patients. TUDRIQEV is indicated in combination with nivolumab after progression on a PD-1-blocking antibody-based regimen, with no requirement for prior BRAF treatment, and can be injected into superficial, deep and visceral lesions, including lung and liver. Patients can be retreated if clinically appropriate.
• Rapid and broad payer coverage facilitated by NCCN guideline inclusion. Multiple payer policies have been published covering TUDRIQEV to label. TUDRIQEV has been listed in the NCCN Clinical Practice Guidelines in Oncology as a category 2A recommendation.
• IGNYTE-3 confirmatory study remains on track. The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician’s choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment is actively enrolling. The primary endpoint is overall survival, and key secondary endpoints are progression free survival and overall response rate.

RP2

• REVEAL Study: The registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling. The trial is evaluating RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab. The primary endpoints of the trial are overall survival and progression free survival, and key secondary endpoints are overall response rate and disease control rate.

Financial Highlights

• Cash Position: As of September 30, 2026, cash and cash equivalents were $307.8 million, as compared to cash, cash equivalents and short-term investments of $268.9 million as of fiscal year ended March 31, 2026. The increase in cash balance was a result of approximately net $141.0 million in proceeds from the Company’s offering of common stock and pre-funded warrants in August 2026, as well as $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026, partially offset by cash burn related to operating activities in advancing the company’s clinical development plans.

  We expect that our existing cash and cash equivalents will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, which includes the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes.

• R&D Expenses: Research and development expenses were $34.4 million for the fiscal second quarter ended September 30, 2026, and $57.9 million for the fiscal second quarter ended September 30, 2025. This decrease was primarily due to a decrease in personnel related and other costs, as well as a decrease in direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies. Research and development expenses included $4.9 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.
• S,G&A Expenses: Selling, general and administrative expenses were $21.9 million for the fiscal second quarter ended September 30, 2026, as compared to $26.4 million for the fiscal second quarter ended September 30, 2025. Selling, general and administrative expenses included $5.7 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.
• Net Loss: Net loss was $57.1 million for the fiscal second quarter ended September 30, 2026 and $83.1 million for the fiscal second quarter ended September 30, 2025.

About TUDRIQEV™ (vusolimogene oderparepvec-wtpg)

TUDRIQEV is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the ICP47 inhibitor of antigen presentation are deleted. TUDRIQEV preferentially replicates within tumors, leading to tumor lysis and release of tumor and viral antigens. In combination with nivolumab, TUDRIQEV may promote an anti-tumor immune response in the anti-PD-1-resistant setting. For more information, visit Tudriqev.com.

INDICATION

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions
Accidental exposure of TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Herpetic infection or reactivation: Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted. Injection procedure complications: Complications related to injection procedure have occurred, including hemorrhage, infection, and visceral injury. Patients should be monitored for signs and symptoms of visceral injury (eg, pneumothorax) during and after TUDRIQEV administration and managed according to clinical practice. Immune-mediated events: In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab.

Adverse Reactions
Most common non-laboratory adverse reactions reported in more than 10% of patients were fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1).

Drug Interactions
Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

Special Populations
Advise females and males of reproductive potential to use effective contraception during treatment with TUDRIQEV and for 90 days after the last dose.

About RP2

RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com. 

Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings or appeals of decisions in any such proceedings, and our expectations about our cash runway, our ability to execute on our strategic or financial initiatives, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com 

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com 

Replimune Group, Inc. Condensed Consolidated Statements of Operations (Amounts in thousands, except share and per share amounts) (Unaudited)
	Three Months Ended September 30,								Six Months Ended September 30,
		2026				2025				2026				2025
Operating expenses:
Research and development	$	34,365			$	57,877			$	83,644			$	115,721
Selling, general and administrative		21,916				26,414				40,885				58,994
Total operating expenses		56,281				84,291				124,529				174,715
Loss from operations		(56,281	)			(84,291	)			(124,529	)			(174,715	)
Other income (expense):
Research and development incentives		238				377				534				797
Investment income		1,880				3,696				3,840				8,411
Interest expense on finance lease liability		(502	)			(518	)			(1,007	)			(1,039	)
Interest expense on debt obligations		(2,523	)			(1,488	)			(5,104	)			(2,963	)
Other income (expense), net		67				(876	)			(621	)			(284	)
Total other (expense) income, net		(840	)			1,191				(2,358	)			4,922
Net loss	$	(57,121	)		$	(83,100	)		$	(126,887	)		$	(169,793	)
Net loss per common share, basic and diluted	$	(0.54	)		$	(0.90	)		$	(1.26	)		$	(1.85	)
Weighted average common shares outstanding, basic and diluted		105,176,101				91,915,769				101,042,985				91,717,076

Replimune Group, Inc. Condensed Consolidated Balance Sheets (Amounts In thousands, except share and per share amounts) (Unaudited)
	September 30, 2026			March 31, 2026
	(in thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments	$	307,833		$	268,889
Working capital		278,482			220,891
Total assets		373,940			332,388
Total stockholders’ equity		204,778			166,160

DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.  

Delivering On Our Performance Objectives
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA^®/VAZKEPA^® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value,” said Aaron Berg, President & Chief Executive Officer. “International in-market demand grew at a double-digit pace across our partner network reflecting increased adoption by patients and prescribers, and we maintained leadership in the U.S. IPE market amid pricing pressure from generic competition.”   

($ in millions)	Q4 2025	Q1 2026	Q2 2026	Q3 2026	FY 2026 Expectations
Operating Expense Reduction from Prior Year Period, Excluding Restructuring Charges	(41)%	(38)%	(38)%	(22)%	Further reductions in Q4
Net Cash Provided by Operating Activities	$7.0	$6.4	$6.6	$9.2	Positive for Q4
Cash, Cash Equivalents & Short-Term Investments	$302.6	$307.8	$314.6	$323.4	~$330
Inventory	$195.9	$183.6	$164.1	$158.9	Maintain disciplined approach that aligns with demand and reflects improved contracting
Debt	$0	$0	$0	$0	Remain debt free

Global Commercial Momentum and Continued U.S. Market Leadership

• In Europe, in-market demand for VAZKEPA increased by an estimated 68% in Q3 2026 compared with Q3 2025, reflecting strong execution and increased investment by Recordati S.p.A. (“Recordati”) under our exclusive license and supply agreement. Momentum was driven by strong performance in Spain, the UK and Italy. Growth in Europe significantly exceeded the historical European growth rates achieved by Amarin before the partnership began in Q2 2025.
• As of September 30, 2026, VASCEPA/VAZKEPA was commercially available in 22 countries worldwide, including 11 European countries through Recordati. The Recordati agreement covers 59 countries with patent protection for VASCEPA / VAZKEPA extending through 2039 in these markets.
• VAZKEPA was launched into the private pay market in Poland (non-reimbursed) during the month of October. Recordati is currently advancing pricing, reimbursement and market access activities to support planned launches in additional licensed markets. These launches, when completed, are expected to increase the number of countries where VAZKEPA will be commercially available.
• Across our global partner network, in-market demand for VASCEPA/VAZKEPA increased by an estimated 55% in Q3 2026 compared with Q3 2025.
• In the United States, the Company’s leading share of the IPE market was 47% in Q3 2026, reinforcing the power of VASCEPA’s clinical differentiation, the trust of prescribers and patients, our proven ability to reliably supply the market and the disciplined execution of our commercial team.
• The Company expects U.S. volumes to remain broadly stable for the remainder of FY 2026.

Financial Highlights

($ in millions)	Q3 2026	Q3 2025		% Change	9 Mos. 2026		9 Mos.   2025		% Change
Total Net Revenue	$39.6	$49.7		(20)%	$126.9		$164.4		(23)%
Operating Expenses	$18.5	$33.3		(44)%	$74.6		$141.5		(47)%
Operating Loss	$(2.4)	$(11.1)		79%	$(25.7)		$(43.8)		41%
Operating Margin % *	(6)%	(22)%		16 pts	(20)%		(27)%		7 pts
Net Income (Loss)	$0.2	$(7.7)		103%	$(17.9)		$(37.6)		52%
Net Margin	1%	(16)%		16 pts	(14)%		(23)%		9 pts
* Operating margin is calculated as operating loss divided by total net revenue

Peter Fishman, Amarin’s Chief Financial Officer, said, “We reported our first profitable quarter in over two years, reflecting our lower expense base and the absence of charges following the completion of our previously announced $70 million cost savings initiatives. We generated positive free cash flow for the fourth consecutive quarter. Our cash balance now exceeds $323 million and our balance sheet remains debt-free.”

He continued, “We are encouraged by the in-market demand growth for VASCEPA/VAZKEPA across Europe and the rest of the world, reflecting its expanding market presence. We expect this growth to support increased partner supply purchases and related revenue over time as our partner-led sales model matures. The timing and level of product revenue will continue to reflect factors outside our direct control, including partner inventory levels, ordering patterns, as well as market access and pricing.  In the U.S., we have efficiently maintained a market leading position in a highly competitive environment which continues to further strengthen our financial foundation.”

Financial Performance
Comparisons to comparable 2025 periods, unless otherwise stated

Revenues

($ in millions)	Q3 2026	Q3 2025	% Change	9 Mos. 2026	9 Mos. 2025	% Change
Product Revenue, net:
U.S. Europe Rest-of-World (ROW)	$28.5 $3.7 $4.7	$40.9 $4.1 $3.6	(30)% (9)% 29%	$96.4 $14.1 $8.8	$113.0 $16.1 $7.1	(15)% (12)% 24%
Total Product Revenue, net	$36.9	$48.6	(24)%	$119.3	$136.2	(12)%
Licensing & Royalties	$2.7	$1.1	139%	$7.6	$28.2	(73)%
Total Net Revenue	$39.6	$49.7	(20)%	$126.9	$164.4	(23)%

Total Net Revenue: U.S. sales of VASCEPA declined by 30% due largely to lower net pricing associated with changes in customer mix, driven largely by continued generic competition. Sales in Europe also decreased, which reflected launch inventory purchases in last year’s third quarter associated with the commencement of our partnered strategy. ROW sales rose 29% due to the strength and execution of our partners in their respective markets. The Company expects combined in-market demand across all its global partner markets to continue to grow on a sequential quarterly basis.

Licensing and royalty revenue in Q3 2026 rose 139% to $2.7 million and reflected increased partner sales within their respective territories.

Operating Expenses
Comparisons to comparable 2025 periods, unless otherwise stated

($ in millions)	Q3 2026	Q3 2025		% Change	9 Mos. 2026		9 Mos.   2025		% Change
COGS	$23.4	$27.5		(15)%	$78.0		$66.7		17%
SG&A	$14.3	$19.7		(27)%	$57.6		$94.9		(39)%
R&D	$4.2	$4.2		0%	$13.6		$14.4		(5)%
Restructuring	—	$9.4		NM	$3.4		$32.2		(90)%
Total Operating Expenses *	$18.5	$33.3		(44)%	$74.6		$141.5		(47)%
* Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses. NM – Not Meaningful

COGS: Decreased 15% to $23.4 million, reflecting lower product volumes and the positive effect of more favorable API purchasing terms. We expect these API-related benefits to increase as production volumes grow, driving further cost efficiencies.

SG&A: Decreased 27% to $14.3 million, reflecting the benefits of our Global Restructuring activities completed in Q2 2026 in connection with the execution of the Recordati agreement.

R&D: Consistent with the prior year period.

A Stronger Platform for Strategic Value Creation
Mr. Berg continued, “Our financial results demonstrate the tremendous progress we have made to date, and we believe Amarin is in a stronger position than at any point in our recent history. Building on that and guided by a clear mandate to maximize shareholder value, we continue to work closely with Barclays, our exclusive financial advisor, and remain focused on working through these efforts in a timely and disciplined manner.”

Exploring Additional Therapeutic Applications for IPE 
On October 25, 2026, we announced findings from the EPA for Metastasis Trial 2 (EMT2), which was an investigator-initiated Phase 3 trial sponsored and conducted by the University of Leeds and funded by Yorkshire Cancer Research and presented as a late breaker at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. Read the full press release here.

The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA, and its potential role as an add-on therapy in improving outcomes for patients undergoing liver resection and standard of care treatment for colorectal cancer liver metastases (CRCLM). The investigational medicinal product used in EMT2 was VASCEPA in the same dosage utilized in the landmark REDUCE-IT cardiovascular outcomes study.

“Our focus remains on patients and their unmet needs, and we are energized by the potential of new possibilities for VASCEPA suggested by the outcome of this study,” said Mr. Berg. “We have long believed that we have a special molecule in IPE, and this study reinforces that conviction by pointing to potential new therapeutic applications for VASCEPA/VAZKEPA. Patent protection in Europe through 2039 provides a durable foundation to evaluate opportunities with high unmet patient needs and their potential to deliver long-term value for patients and shareholders.”

Third Quarter 2026 Financial Results Conference Call and Webcast Information
Amarin will host a conference call on October 28, 2026, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the Company’s website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 314562. A replay of the webcast will be made available until April 28, 2027. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 54490. A replay of the call will also be available through the Company’s website shortly after the call. 

About Amarin
At the Heart of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide.  Our flagship oral prescription therapy, VASCEPA^® (icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 32 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA^® across nearly 100 markets worldwide. For more information, visit www.amarincorp.com and follow Amarin on LinkedIn, X, Facebook. To be added to the Company’s email list and receive news directly, please visit  https://investors.amarincorp.com/email-alerts.  

About VASCEPA^®/VAZKEPA^® (icosapent ethyl) Capsules 
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than thirty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021, marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Slovenia, Romania, Denmark and Austria.

United States Indications and Limitation of Use

VASCEPA is indicated:  

• As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.   
• As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.  

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information 

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.
• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
• Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM

Europe 
For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA^® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf 

Globally, prescribing information varies; refer to the individual country product label for complete information.

Use of Non-GAAP Adjusted Financial Information  
Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure is most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.

Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.

While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.

Forward-Looking Statements 
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s outlook for achievements in 2026 and beyond; Amarin’s overall efforts to expand access and reimbursement to VASCEPA/VAZKEPA across global markets; expectations regarding potential market dynamics, payer behavior, and the competitive landscape; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2025 and subsequent quarterly reports on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Amarin Contact Information  
Media Inquiries:  
Amarin Corporation plc  
PR@amarincorp.com  

Investor Inquiries:
Devin Sullivan & Conor Rodriguez  
The Equity Group on Behalf of Amarin   
devin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com 
Investor.relations@amarincorp.com 

-Tables to Follow-

CONSOLIDATED BALANCE SHEET DATA
(U.S. GAAP)
Unaudited
		September 30, 2026				December 31, 2025
		(in thousands)
ASSETS
Current Assets:
Cash and cash equivalents		$	156,512			$	134,660
Restricted cash			201				201
Short-term investments			166,867				167,929
Accounts receivable, net			111,573				126,832
Inventory			158,850				195,910
Prepaid and other current assets			18,872				24,350
Total current assets			612,875				649,882
Operating lease right-of-use asset			6,082				6,461
Other long-term assets			3,669				1,067
Intangible asset, net			11,455				13,365
TOTAL ASSETS		$	634,081			$	670,775
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	40,429			$	45,355
Accrued expenses and other current liabilities			134,707				149,104
Total current liabilities			175,136				194,459
Long-Term Liabilities:
Long-term operating lease liability			5,353				6,080
Other long-term liabilities			9,180				10,955
Total liabilities			189,669				211,494
Stockholders’ Equity:
Common stock			316,272				310,184
Additional paid-in capital			1,923,521				1,923,801
Treasury stock			(70,120	)			(67,360	)
Accumulated deficit			(1,725,261	)			(1,707,344	)
Total stockholders’ equity			444,412				459,281
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	634,081			$	670,775

CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(U.S. GAAP)
Unaudited
	Three months ended September 30,								Nine months ended September 30,
	(in thousands, except per share amounts)								(in thousands, except per share amounts)
	2026				2025				2026				2025
Product revenue, net	$	36,890			$	48,558			$	119,293			$	136,210
Licensing and royalty revenue	2,660				1,112				7,600				28,217
Total revenue, net	39,550				49,670				126,893				164,427
Less: Cost of goods sold	23,369				27,462				77,954				66,728
Gross margin	16,181				22,208				48,939				97,699
Operating expenses:
Selling, general and administrative (1)	14,336				19,697				57,637				94,944
Research and development (1)	4,205				4,208				13,643				14,435
Restructuring	—				9,406				3,363				32,165
Total operating expenses	18,541				33,311				74,643				141,544
Operating loss	(2,360		)		(11,103		)		(25,704		)		(43,845		)
Interest income, net	2,371				2,783				7,845				8,277
Other income, net	304				205				1,583				372
Income (loss) from operations before taxes	315				(8,115		)		(16,276		)		(35,196		)
(Provision for) benefit from income taxes	(70		)		377				(1,641		)		(2,378		)
Net income (loss)	$	245			$	(7,738	)		$	(17,917	)		$	(37,574	)
Earnings (loss) per Ordinary Share:
Basic	$	0.00			$	(0.02	)		$	(0.04	)		$	(0.09	)
Diluted	$	0.00			$	(0.02	)		$	(0.04	)		$	(0.09	)
Weighted average Ordinary Shares:
Basic	417,766				415,531				420,178				414,607
Diluted	427,856				415,531				420,178				414,607
(1) – Excluding non-cash stock-based compensation, selling, general and administrative expenses were $13,255 and $17,938 for the three months ended September 30, 2026 and 2025, respectively, and research and development expenses were $3,910 and $3,613, respectively, for the same periods.

RECONCILIATION OF NON-GAAP NET INCOME (LOSS)
Unaudited
		Three months ended September 30,								Nine months ended September 30,
		(in thousands, except per share amounts)								(in thousands, except per share amounts)
		2026				2025				2026				2025
Net income (loss) for EPS1 – GAAP			245				(7,738	)			(17,917	)			(37,574	)
Stock-based compensation expense			1,377				2,354				5,773				12,720
Restructuring			—				9,406				3,363				32,165
Litigation-Related Charges			—				—				9,400				—
Licensing Agreement Fees			—				—				—				5,038
ADS Ratio Change Fees			—				—				—				2,015
Net income for EPS1 – non-GAAP		$	1,622			$	4,022			$	619			$	14,364
1basic and diluted
Earnings per Ordinary Share:
Basic – non-GAAP		$	0.00			$	0.01			$	0.00			$	0.03
Diluted – non-GAAP		$	0.00			$	0.01			$	0.00			$	0.03
Earnings per ADS:
Basic – non-GAAP		$	0.08			$	0.19			$	0.03			$	0.69
Diluted – non-GAAP		$	0.08			$	0.19			$	0.03			$	0.69
Weighted average Ordinary Shares:
Basic			417,766				415,531				420,178				414,607
Diluted			427,856				416,117				431,312				415,127